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	Abstract 
 
Creation of the thioether linkage is a fundamental step for the chemical preparation of the bacterial 
quorum sensing molecule S-D-ribosyl-L-homocysteine (SRH). Although previous preparations of SRH 
and its analogues have been reported in the literature, they employ assorted methods with varied results. 
Therefore, a reassessment of the methodology used for synthetic preparation of the thioether bond in 
SRH-like molecules is here considered. This work examines four methods of thioether generation 
following two mechanisms, bimolecular nucleophilic substitution (SN2) and radical-initiated thiol-ene 
coupling, in an attempt to generate SRH in a more efficient and reproducible manner. Both mechanisms 
address key objectives for SRH preparation: consistent production of the target compound in an 
analytically pure form, synthesis from easily obtained commodity materials, and improved understanding 
of each variable involved in creating the thioether bond in this molecule. One application of the thiol-ene 
coupling reaction generates the SRH thioether at a trial scale with a much-improved yield (93% over 
70%) when compared to the most successful reported method to date. Other observations include 
improved understanding of steric effects involved in both mechanisms, optimization of conditions, 
assessment of electrophile choice, and the synthesis of a diastereomer of SRH, which may be considered 
for use in competitive inhibition assays. 
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Chapter 1. Targeting Bacterial Quorum Sensing as an Anti-Infective Strategy 
 
Antibiotic resistance is a major health issue worldwide. Certain strains of bacteria are no longer 
responding to long-used treatments, and infections that were once easily cured are becoming difficult to 
manage. The Infectious Diseases Society of America reports that bacterial evolution against conventional 
therapies is far outpacing the rate of new drug development.1 Meanwhile, an estimated two million 
infections developed annually in the United States are caused by antibiotic-resistant pathogens, resulting 
in at least 23,000 deaths each year.2 The most well-known representation of this health crisis may be the 
emergence of methicillin-resistant Staphylococcus aureus (commonly known as MRSA). During the mid-
1900’s, S. aureus began to develop resistance to penicillin and other related β-lactam antibiotics. 
Evolving over time, some more recent strains have begun to show resistance to even some of the “last 
resort” therapies such as vancomycin.3 
 
While bacteria adapt in order to defend themselves against conventional antibiotic treatments, the 
scientific community continues to explore new molecular pathways as avenues to treat infections. 
Bacterial quorum sensing (QS) is one enticing target option. QS is a molecular signaling system in which 
bacteria secrete small organic molecules called autoinducers (AI’s) into their environment. When a 
microbial population grows sufficiently large, the resulting concentration of secreted AI’s surpasses a 
threshold value that is correlated to an optimal cell density (Figure 1). Once that signal threshold level is 
achieved, each individual member of the community of bacteria is able to detect the AI, resulting in the 
collective regulation of gene expression that enables the colony members to behave in concert.4-6 
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Figure 1. Bacterial AI biosynthesis and quorum sensing AI’s (blue crosses) are biosynthesized and 
secreted by bacteria (green circles) into the surrounding environment. After a certain concentration of 
AI’s has accumulated in proportion to cell density, a receptor (pink triangles) located at the surface 
(depicted above, i.e., LuxN, LsrB) or within the cytoplasm (not depicted, i.e., LuxR) of each bacterium is 
able to detect the AI’s. In QS-active species, this detection triggers a regulation in gene expression and 
associated behavioral changes throughout the colony.7 
 
Both Gram-negative and Gram-positive species utilize AI’s for QS, and various bacterial behaviors have 
been tied to AI-regulated activity. While some bacteria use QS circuits for benign behaviors such as 
bioluminescence, others commonly regulate virulence factor expression. Table 1 lists a selection of QS-
regulated traits observed across the bacterial kingdom. 
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Table 1. Behaviors associated with QS in Gram-positive and Gram-negative species 
Organism Gram Identity Regulated Behavior7 
 
Bacillus 
thuringiensis 
 
Enterococcus 
faecalis 
 
Escherichia coli 
 
Pantoea stewartii 
 
Salmonella 
Typhimurium 
 
Staphylococcus 
aureus 
 
Streptococcus 
pneumoniae 
 
Vibrio cholerae 
 
Vibrio harveyi 
 
Positive 
 
 
Positive 
 
 
Negative 
 
Negative 
 
Negative 
 
 
Positive 
 
 
Positive 
 
 
Negative 
 
Negative 
 
Sporulation8 
 
 
Conjugation & Adhesion9 
 
 
Motility & Acid Resistance10 
 
Adhesion11 
 
Virulence & Motility12 
 
 
Exotoxins & Biofilm13 
 
 
Competence14 
 
 
Biofilm & Virulence15 
 
Bioluminescence16 
 
 
Targeting QS as a new anti-infective strategy against associated virulent behaviors is attractive 
particularly due to its potential for the development of a new class of non-lethal antibiotics. Upon 
blocking the QS signal, it is reasonable to predict that the expression of virulent traits may be disrupted 
without actually killing the bacteria, as QS-regulated behaviors are not generally critical to survival.7 This 
non-lethal approach to treatment could subdue infection without “selecting for” chemically resistant 
strains that possess an incentive to evolve antibiotic resistant traits.17 In fact, development of resistance to 
an anti-cooperative treatment (i.e., resisting the prevention of activity induced by QS) could actually 
prove disadvantageous to a bacterium expending its resources in an otherwise competitive environment.18 
 
1.1 Autoinducer-2 and System Two QS 
While many AI’s are species-specific (i.e., operate among only one species of bacteria), the system two 
QS signaling molecule, autoinducer-2 (AI-2), facilitates interspecies cell-to-cell communication.19 
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Hundreds of publications have reviewed and studied system two signaling, and behaviors in dozens of 
bacterial species (several of which are virulent) have been attributed to AI-2 induction.20 For this reason, 
it is believed that system two QS could act as something of a broad spectrum target for a potential 
therapy. It is worth noting that AI-2 has been shown to operate in concurrence with other factors to 
regulate behavior changes, suggesting that targeting AI-2 alone may not eliminate a particular phenotype. 
For example, Vibrio harveyi requires three individual signaling molecules, AI-2, CAI-1, and HAI-1, to act 
synergistically in order to elicit its maximum bioluminescence response.21 A list of representative 
behaviors affected by AI-2 activated gene expression is summarized in Table 2.5,7,20 
 
Table 2. Selected traits affected by AI-2 regulated gene expression 
Bacterial Species Phenotype Affected by AI-25,20 
Actinobacillus pleuropneumoniae 
Borrelia burgdorferi 
Clostridium perfringens 
Escherichia coli (EHEC) 
Helicobacter pylori 
Pseudomonas aeruginosa 
Salmonella enterica Typhimurium 
Staphylococcus aureus 
Streptococcus intermedius 
Vibrio cholerae 
Formation of Biofilm, Adhesion22 
 
Lipoprotein Expression23 
 
Toxin Production24 
 
Motility, Toxic Protein Production, Attachment25 
 
Motility26 
 
 
Virulence Factor Expression27 
 
Virulence Factor Expression28 
 
Capsule Structure29 
 
Biofilm Production, Antibiotic Susceptibility30 
 
Biofilm Production, Virulence factors, Competence31 
 
Development of an anti-infective treatment directed at a particular component involved in the AI-2 circuit 
could proceed in a number of ways. Targets include cellular factors involved in the synthesis or the 
detection of the QS signal. The following section provides a brief overview of the production and activity 
of AI-2.  
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1.1.1 Biosynthesis, Detection, and Function of AI-2 in vivo 
AI-2 is biosynthesized in vivo (Figure 2A) as a catabolite within a variation of the activated methyl cycle 
(AMC) that is specific to bacteria. Universally, demethylation of the methyl donor S-adenosylmethionine 
(SAM) results in the production of the toxic intermediate S-adenosylhomocysteine (SAH).19,20 Eukaryotes 
and some bacteria then break down SAH in a single step using the enzyme SAH hydrolase. This enzyme 
cleaves SAH into adenosine (Ado) and L-homocysteine (L-HCys), which can then be reused as cellular 
metabolites.5 
 
 
 
 
A 
 
 
 
 
 
 
 
B 
 
Figure 2. Biosynthetic production of AI-2 (A) Detoxification pathway of the AMC proceeds in one of 
two variations. The two step pathway using the enzymes Pfs and LuxS results in the formation of DPD. 
(B) An unstable molecule, DPD spontaneously cyclizes in aqueous solution. To date, two signaling 
molecules, R-THMF and S-THMF-borate, have been identified as AI-2 forms detectable by bacteria.32,33 
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Other bacteria detoxify SAH in two steps: First, SAH is hydrolyzed by the Pfs enzyme, producing 
adenine (Ad) and S-D-ribosyl-L-homocysteine (SRH). In a second step, SRH is further catabolized by the 
enzyme S-ribosylhomocysteinase (LuxS) into L-HCys and 4(S),5-dihydroxy-2,3-pentanedione (DPD). 
DPD is an unstable compound that spontaneously cyclizes in aqueous environments, resulting in a set of 
equilibrating chemical species that exist collectively as “AI-2” (Figure 2B).5,20 
 
1.1.1.1 Discerning a Target Option in System Two QS 
The luxS gene has been identified in over half of known genomes across the bacterial kingdom.34 Within 
bacteria, the LuxS enzyme universally generates DPD from SRH (Figure 2B). The equilibrating nature of 
AI-2 allows various species of bacteria to sense the same chemical signal, despite the expression of 
different AI-2 receptor proteins.20 To date, two conformations of AI-2 have been isolated which bind 
different AI-2 receptors. Chen et al. found that the species Vibrio harveyi binds a borate-containing form 
of AI-2 called S-THMF-borate (Figure 2B) using the receptor LuxP.32 Miller et al. later identified the 
receptor LsrB in S. Typhimurium, and characterized the bound conformation of AI-2 as R-THMF (Figure 
2B).33 Considering this example of two AI-2-detecting species with differences in both their receptors and 
the AI-2 conformation they are able to detect, the observation that the AI-2 biosynthesized by S. 
Typhimurium invoked QS-regulated behavior changes in V. harveyi is indicative of the conformational 
dynamism of DPD in biological systems. When a strain of V. harveyi deficient in the ability to produce 
endogenous AI-2 was treated with in vitro synthesized DPD, endogenously-produced LuxP ligand, or 
endogenously-produced LsrB ligand, each trial demonstrated a quantified bioluminescence response to all 
treatments (also dependent on the boron equilibrium). This dynamic equilibrium between DPD, R-THMF, 
and S-THMF-borate33 indicates that targeting LuxS could lead to the development of a single inhibitor 
with the ability to slow or stop the production of AI-2 in many bacteria, broadly treating infections 
induced by a number of species without the need for multiple receptor-specific therapies. 
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1.1.1.2 Molecular Role of AI-2 in vivo 
There has been some debate over whether AI-2 is an important QS signal or simply a byproduct of the 
essential SAH detoxification mechanism.20 The ideas and evidence surrounding this debate are vast and 
complex. A selection of interesting arguments is summarized below: 
• One hypothesis suggests that, in certain cases, a phenotype resembling a gene-activated behavior 
change could arise as the result of a defective metabolic route. This idea has been countered in a 
number of cases by restoring function in mutants lacking the ability to produce AI-2 by 
complementing the mutation with the introduction of chemically-prepared DPD.5 
• The presence of AI-2 can be viewed as a marker for “fitness of population,” non-coincidentally 
produced when bacterial populations would most benefit from collective gene regulation. 
Increased methylation is correlated with cellular growth occurring in the log phase, and microbial 
populations are often successful when behavioral changes occur within a thriving population.5,20  
• Some bacteria (e.g., P. aeruginosa) degrade or uptake AI-2 as a possible carbon source, but this 
behavior has also been suggested as a means of depleting the communal AI-2 signal for the 
benefit of a particular species’ advantage in colonization.35 Even as a metabolic byproduct, the 
presence of AI-2 could serve as a signal to other species benefiting somehow from the makeup of 
a complex bacterial community.5 
• Another interesting question regarding the signaling nature of AI-2 is the rationale behind the 
evolution of the two-step detoxification mechanism. If SAH is easily detoxified in one step by 
SAH hydrolase, is there a significance to the evolution of a two-step sequence for another 
purpose (i.e., signaling), or is this process genetically conserved simply because of its 
involvement in the AMC?5,36 
• LuxS is not essential to survival, but there could be an unknown benefit for use of AI-2 as a 
metabolite, such as for the biosynthesis of sulfur-containing amino acids.36 
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The fact that SAM is also a precursor to other types of species-specific AI’s suggests there is some 
relationship between the AMC and QS.5,20 Nevertheless, while the function of AI-2 has not been 
universally made clear, evidence does suggest that in many circumstances AI-2 is an important factor in 
QS-regulated gene expression. 
 
1.1.2 Targeting and Suppressing System Two QS 
There are several intriguing facts about system two QS and its suitability as an anti-infective target. 
Namely, it is important for the coordination of certain virulent behaviors (Table 2). AI-2 is utilized by a 
significant number of bacterial species (including Gram-negative and Gram-positive pathogens), and the 
absence of LuxS in eukaryotes could enable it to be targeted without affecting regular cellular function in 
humans and other species.7 These features make system two QS a worthy subject for drug development 
research.  
 
To this end, studies blocking AI-2 detection or using null mutant luxS strains have shown some 
interesting results regarding bacterial response to antibiotic treatments. For example, an increase in 
susceptibility to conventional antibiotics in luxS mutants was demonstrated by Nibras et al.37 In these 
studies, Streptococcus anginosus luxS mutants showed increased susceptibility to two common antibiotics 
(erythromycin and ampicillin) when compared to a wild-type strain. Furthermore, when QS was 
complemented in the same S. anginosus luxS mutant by the addition of wild-type supernatant (presumably 
containing AI-2) or by the addition of DPD, susceptibility to both antibiotics decreased. This indicated 
that QS-based therapies may also be useful in weakening virulent populations to a level at which existing 
antibiotics may prove more effective.  
 
This same trend of using a QS signaling prevention therapy in conjunction with a bactericidal treatment 
was demonstrated using DPD analogues to treat biofilms in combination with the antibiotic gentamicin. 
Here, although E. coli and P. aeruginosa biofilm formation were both diminished with treatment of an 
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inhibitory DPD analogue alone, preexisting biofilms exposed to a therapeutic combination of both the 
DPD analogue and gentamicin deteriorated more effectively than when treated with the antibiotic alone.38 
Additionally, these results were acquired using gentamicin in amounts similar to the minimal inhibitory 
concentration required for treatment of these species in the “planktonic” free swimming form rather than 
the increased dosage necessary when treating biofilms. This suggests an anti-QS treatment could improve 
susceptibility to antibiotics while also decreasing the concentration of antibiotic required to treat 
infection, addressing an issue around dosage which can be simultaneously detrimental to non-virulent 
microflora.39 
 
1.2 Competitive Inhibition of LuxS Using SRH Analogues 
Past research targeting the LuxS enzyme has resulted in the development of a number of SRH 
analogues.40-44 In modifying the LuxS substrate, SRH, the objective is to create a competitive inhibitor 
with the ability to bind the LuxS active site and significantly slow AI-2 production from endogenous 
SRH.40 Such SRH analogues can be strategically designed to impact a particular aspect of LuxS catabolic 
activity, since the mechanistic action of the enzyme has been well-studied. 
 
1.2.1 The LuxS Mechanism 
The crystal structure of the LuxS enzyme has been determined by a number of groups.45 The enzyme 
exists as a homodimer, with its pair of active sites utilizing residues from both peptide subunits. Pei’s 
group has elucidated a mechanism for SRH metabolism (Figure 3) guided by these crystal structures and 
by the identification of catalytically-competent intermediates.46,47 Catalysis by LuxS utilizes an iron (II) 
ion cofactor along with key amino acid residues E57 (α-subunit) and C84 (β-subunit). These components 
assist in the migration of the carbonyl group from the C-1 aldehyde to the C-3 position on the ribose 
moiety of the SRH open chain. Ultimately β-elimination cleaves the thioether to yield L-HCys and a DPD 
tautomer.46,48 
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Figure 3. Catalytic mechanism of LuxS deduced by Pei and coworkers Within the active site of LuxS, 
an iron (II) ion (represented Fe2+) in conjunction with a glutamate residue at position 57 on the α-subunit 
(E57) and a cysteine at position 84 on the β-subunit (C84) assist in an eventual β-elimination whereby L-
HCys and DPD and produced from SRH (adapted from Pei).46 
 
Because the ribose moiety of SRH undergoes many intramolecular conversions on the path to eventual β-
elimination of L-HCys to produce DPD, many SRH analogues have been developed with modification 
about the carbohydrate moiety in efforts to prohibit this sequence of reactions.40-44 Presented in Figure 4 
are some of the molecules developed with this objective. By removing or replacing key functional groups 
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on SRH, previously generated analogues were designed to directly affect the catalytic mechanism. These 
works have resulted in a number of SRH analogues possessing competitive inhibitory character, although 
in moderate concentrations.40-43,49 
A B C D 
    
Figure 4. SRH analogues modified at the ribose moiety A selection of SRH analogues with alteration 
in the carbohydrate moiety. Each has demonstrated a degree of competitive inhibition of the LuxS active 
site.40-43 
 
The most potent competitive inhibitor developed to date (Figure 4A) was reported by Shen, et al.42 When 
evaluated in vitro by an assay using B. subtilis LuxS, KI values were reported in the submicromolar range 
when tested against SRH for both the Co(II) form of the enzyme (KI = 0.37 +/- 0.04 µM) and with the 
native Fe(II) form (KI = 0.43 +/- 0.02 µM). 
 
1.2.2 Ellman’s Bioassay for LuxS Activity 
The Ellman’s assay provides a method to quantify free thiols and has been applied to measure the activity 
of the LuxS enzyme in vitro. When LuxS cleaves the SRH thioether bond, DPD and L-HCys are released. 
The Ellman’s assay uses 5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB) to react with available thiols, in this 
case present on the liberated L-HCys. This reaction forms a stoichiometrically equivalent pigmented ion 
(NTB) quantifiable by colorimetric spectroscopy at 412 nm, which can be used to determine the 
equivalent concentration of AI-2 released by LuxS in the presence of SRH.50 
 
Figure 5. The Ellman’s assay applied to LuxS Activity DTNB binds the thiol of L-HCys, releasing the 
measurable pigmented ion 2-nitro-5-thiobenzoate (NTB). This is stoichiometrically equivalent to the 
amount of DPD released from the activity of LuxS.51 
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This test may be also used to measure the ability of molecules to inhibit LuxS. An inhibitor may be 
introduced to the assay mixture, where it can compete with SRH for the enzyme and reduce the release of 
HCys and AI-2.41-43 The result is a decreased absorbance at 412 nm. 
 
1.3 Chemical Synthesis of SRH 
The work performed for this thesis focuses on the need for a robust SRH synthesis. There are two desired 
outcomes within this goal. First, in order to screen LuxS activity and the inhibitory characteristics of SRH 
analogues in vitro, the Ellman’s assay requires the use of significant quantities of SRH. Ideally, this SRH 
should be rigorously evaluated for purity and aliquotted exactly for reliable KM (activity) and KI 
(inhibition) determination. Thus, the desire to manufacture SRH in analytically pure, stable, and 
measureable form with the best possible yield and by a cost effective route was prioritized. Second, upon 
trials of various methods available for generating the SRH scaffold, in particular by creation of the central 
thioether bond, the complexity of the synthesis of SRH-like compounds might be better understood and 
applied to the thioether creation for future candidate LuxS analogues.  
 
1.3.1 Routes to Thioether Generation 
Past reports of the preparation of SRH and its analogues have employed a number of different strategies. 
At the core of each exists the challenge of producing the thioether carbon-sulfur bond with high 
efficiency. Consideration of C-S coupling from a biological perspective is possible, but is limited to a 
particular enzyme or specific amino acid residue to form thioether linkages in aqueous matrices. While 
SRH has been successfully produced enzymatically from SAH in situ, its final concentration can only be 
estimated by assuming quantitative conversion by the enzyme.43,50 
 
From a traditional synthetic perspective, a number of thioether-generating mechanisms are available; the 
challenge is identifying which can be applied successfully and with good yield for the preparation of SRH 
with limited competing reactions, byproducts, or undesired stereochemical outcomes. Additionally, some 
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mechanisms are demonstrated to be robust and yield good results, but they rely on functional groups that 
are impractical for our synthesis (i.e., thioether generation using aryl thiols). One such example, 
represented in Scheme 1A, is a one-pot reaction by Cheng et al. which is able to join thioether bonds 
using aryl thiols in a Grignard reaction in the presence of N-chlorosuccinimide (NCS).52  
 
Tabor reviewed multiple approaches used for generating thioethers between amino acids for lantibiotic 
development, and provided much insight around synthetic strategies for stereospecific targets requiring 
protection on amino and carboxylate groups.53 In her review, examples of Michael addition approaches 
were demonstrated in good yield, but have resulted in non-stereospecific outcomes, such as the mixture of 
diastereomers, 5 (2:3 ratio), resulting from work by Bradley and coworkers54 presented in Scheme 1B. 
Furthermore, methods using desulfurization of disulfides may yield target products, but result in poor 
yields due to reaction reversibility and would also narrow the options for the choice of protecting groups 
available. Olsen et al. used this method to create unsymmetrical lanthionines for lantibiotic research 
(Scheme 1C).55 Tabor also reviewed SN2 couplings, which have worked in applications to lantibiotic 
research, although many variables must be optimized for the specific reaction being performed. These 
include close monitoring of reaction sensitivity due to conditions, troubleshooting protecting group 
options, steric effects, and electrophile choice, all of which contribute to the level of success and potential 
for competing reactions.53 Again citing lanthionine synthesis, Zhu and Schmidt used sodium bicarbonate 
as a base in a SN2 reaction between starting components 10 and 4 to obtain a single stereoisomer of the 
desired product 11 (Scheme 1D).56  
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A 
 
B 
 
C 
 
D 
 
E 
 
                                        12                                                                                 13 
Scheme 1. Sample applications of various mechanisms for thioether synthesis52-57 (A) An effective 
synthetic approach to thioether formation specific for use with aryl-thiols. Tabor reviewed the use of (B) 
Michael addition, (C) desulfurization of differential disulfides, and (D) nucleophilic substitution for 
thioether development applicable to lantibiotic research. (E) The thiol-ene coupling reaction may be 
applied to biological molecules demonstrated by Triola et al. 
 
An adaptation of the previously mentioned Michael addition is the thiol-ene coupling reaction (TEC), 
which may be propagated by use of a radical mechanism. Like the Michael addition, these reactions may 
result in undesired stereochemistry, although they can be used under mild conditions with fast and good 
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yielding outcomes.57 Among these examples is the report by Triola et al., who created cysteine derivatives 
(i.e., target molecule 13) conjugated with S-linked alkyl groups utilizing 2,2’-azobis(2-
methylpropionitrile) (AIBN) as the radical initiator (Scheme 1E).57 
 
While the previously listed mechanisms for thioether formation are not exhaustive (i.e., unmentioned 
organometallic reactions), two strategies were determined to be most suitable for SRH synthetic studies 
after consideration of reaction efficiency, necessary purification steps, cost, number of intermediates 
involved, and relationship to the existing groundwork research previously performed in our lab. This 
thesis follows the application of the bimolecular nucleophilic substitution (SN2) and the thiol-ene coupling 
(TEC) reaction to SRH synthesis. 
 
1.3.2 Groundwork SRH Thioether Generation by Bimolecular Nucleophilic Substitution  
Acquisition of SRH by means of the SN2 mechanism was first demonstrated in low yield by Guillerm and 
Allart (Scheme 2A).58 A tritium-labeled SRH was created by heating tosyl-activated electrophile 14 in 
solution with thiolate nucleophile 15, yielding protected derivative 16 in 22% yield. After acid 
deprotection of 16 (not shown) and subsequent lyophilization, the tritium-labeled SRH was isolated in 5% 
overall yield. 
 
 
A 
              
           14                              15                                                                       16 
 
 
22% 
 
 
B 
              
          17                              18                                                                      19a 
 
 
 
50-70% 
Scheme 2. Early SRH thioether generation58,59 (A) Tritium-labeled protected SRH 16 was synthesized 
by Guillerm and Allart (B) Mitsunobu-type synthesis of 19a was demonstrated by Zhao et al. 
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Later Zhao et al. improved SRH synthesis by employing a Mitsunobu-type coupling reaction to create a 
protected SRH from starting components 17 and 18 (Scheme 2B).59 The disulfide bond of the 
homocystine derivative 18 is reduced by triethylphosphine, generating a thiolate nucleophile in situ which 
reacts in the presence of pyridine in an SN2-fashion with the protected ribose 17. After flash column 
chromatography, the protected product 19a was isolated with improved yield (50-70%) over Guillerm and 
Allart’s coupling and later deprotected in two steps to a SRH.TFA salt (not shown).59  
 
Under trials performed in our lab, the Zhao strategy was both inconvenient in practice and inconsistent 
with the published results. Furthermore, it proceeds over many days, the progress of the reaction is not 
easily monitored due to apparent decomposition, and two steps are necessary to deprotect the SRH 
derivative 19a. The reaction also uses an excess of 18 derived from the specialty chemical L,L-
homocystine. For these reasons the motivation existed to develop a more straightforward synthesis of 
SRH that follows a more traditional SN2 mechanism, uses more easily accessible starting materials, and 
has the ability to globally deprotect the new protected SRH molecule to high purity in a single step. 
 
Initiating investigation into the desired improvement of SRH synthesis, former graduate student Ruoyi 
Liu performed work in our lab by adapting ideas from previously reported publications.60 While 
attempting the Zhao method of C – S bond formation, decomposition was observed. After establishing 
that the disulfide was successfully cleaved by the phosphine reagent, it was suspected that the native 
unactivated 5’-hydroxyl group on the ribose derivative 17 might account for the poor nucleophilic 
coupling. Influenced by the work of Wnuk41 in the context of SRH analogue preparation, Liu proposed 
that introduction of a better leaving group would improve the coupling. After ascertaining that the 
introduction of the mesylate leaving group onto ribose component 20a successfully promoted SRH 
synthesis using unprotected HCys under basic conditions (not quantified, Scheme 3A), attention was 
turned toward protecting groups for the amino acid. Although coupling proved successful without 
protecting groups present on the HCys moiety, the yield could not be quantified due to purification 
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problems resulting from the absence of HCys protection on product 21 and complications from byproduct 
contamination. Derivative 22 using methyl ester protection of the carboxyl group of HCys then failed to 
produce a coupled product under the alkaline reaction conditions used (Scheme 3B). This trend continued 
to be problematic when applied to SRH analogue production. Trials using the typical SN2 strategy for the 
coupling of thiol 23 and sulfonates 20a or 20b (Scheme 3C) resulted in no reaction.60 It was proposed that 
protecting group identities were significant contributors to the failure of these couplings. 
 
A 
 
                                              20a                                                               21 
 
B 
 
            22                   20a (R = Ms)                                                            19a 
                                   20b (R = Ts) 
 
C 
 
           23                  20a (R = Ms)                                                               24 
                                 20b (R = Ts) 
 
D 
 
            7                        20a (R = Ms)                                                        19b 
                                      20b (R = Ts) 
          
 
 
70% 
                              
Scheme 3. Investigation into thioether coupling by SN260 (A) Successful coupling was observed 
between unprotected HCys and an activated ribose derivative. Under alkaline conditions, amino acid 
protecting groups on the HCys moiety were suspected to impede the successful coupling in (B) protected 
SRH and (C) an SRH analogue. (D) Use of robust protecting groups under basic conditions resulted in 
successful production of protected SRH (up to 70%).  	
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Utilizing the bulky tert-butyl carboxylate protecting group in conjunction with Boc carbamate protection 
on 7, coupling with electrophiles 20a or 20b, Liu was able to successfully prepare the fully protected 
SRH 19b by SN2 in an alkaline environment in 70% yield (from 20b) of the coupling reaction (Scheme 
3D).60 
 
After these key observations were recorded, the focus of future research was directed to understanding the 
effect of each individual variable on this synthesis. Solvent and base identities, as well as equivalent 
reactant concentrations were strategically selected moving forward. Additionally, structural variables 
conducive to promoting successful coupling were also examined such as electrophile leaving group and 
amino acid protecting group identities. 
 
1.3.3 Radical Generation of Thioethers 
An alternate mechanism for formation of thioethers is the use of the intriguing radical-induced thiol-ene 
coupling (TEC) reaction. This “click” reaction couples thiol and olefin components together by a radical 
mechanism.61 Although they are more commonly used in polymer synthetic chemistry, examples of TEC-
based couplings may also be used for application with biological molecules.62 Broadly setting the 
groundwork for our strategy, Dondoni’s group has used TEC to synthesize a number of compounds 
relevant to our research.62-64 In one of these reports by Fiore et al., erythrofuranoside derivative 26 was 
used in the joining of carbohydrates via S-glycoside bond formation with high efficiency using 2,2-
dimethoxy-2-phenylacetophenone (DPAP) as the radical initiator (Scheme 4A).63 In a later work, Fiore 
and coworkers also used DPAP to couple carbohydrates with amino acid residues, including examples 
resulting in the products containing HCys moieties (i.e., product 29, Scheme 4B), mirroring SRH-type 
targets for development in our research.64 These reports assisted in laying out a clear strategy for the 
development of an SRH synthesis that would be expedient and high-yielding, using the mild conditions of 
TEC. 
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A 
                                                                                                               
 
 
 
92% 
 
B 
  
              25                               28                                                                 29 
  
 
       90%             
Scheme 4. Applications of the TEC reaction to biological molecule synthesis63,64 Literature precedents 
have used radical-induced TEC reactions to create (A) S-linked alkyl cysteines (B) S-glycoside bonds, 
and (C) S-glycopeptides. 
  
1.4 Project Summary 
This project employs four routes to generation of the protected SRH thioether, visualized in the 
retrosynthetic breakdown to the necessary coupling components (Figure 6). Two possible approaches are 
outlined for each of the two mechanisms considered.  
 
Figure 6. Retrosynthetic analysis of protected SRH Suggested disconnection of the thioether on either 
side of the sulfur atom leaves carbohydrate and amino acid components. Here two mechanisms are 
considered; SN2 (red and blue) and TEC (purple and orange) mechanisms would generate the thioether in 
the forward direction. 
 
Chapter 2 outlines the methods for the SN2 reaction. After a set of conditions is optimized, the SN2 is 
facilitated with the selection of an electrophile-bound leaving group used to react with a thiol-containing 
coupling partner. The thiol and leaving group functionalities are affixed to opposite partners to test the 
two SN2 approaches (Figure 6, red and blue), and after reversing the nucleophile/electrophile roles, 
theoretic improvements to the SN2 are assessed.  
O
SH
OAc
AcO
AcO
OAc
NH
O
MeO
O
S
OAc
AcO
AcO
OAc
O
OMe
NH
DPAP, 365 nm
CH2Cl2, RT, 30 min.
+
CBz CBz
	 20 
Navigation of the TEC mechanism for thioether generation is described in Chapter 3. Thiol- and alkene-
equipped partners are joined after irradiation of a radical initiator. Again, functional group roles are 
reversed on the coupling components (Figure 6, purple and orange) and tested after investigation into the 
stereochemical outcomes of the TEC synthesis. Optimization considerations are then outlined for the TEC 
reaction and its application to SRH synthesis. 
 
This thesis concludes with notes on efficient thioether generation for SRH synthesis and suggestions for 
further completion of this work. Based upon the information gleaned from the four approaches used in 
this research, future directions on preparation of some analogue options are also outlined, as well as 
suggestions for the possible methods that could be used to prepare those analogues. 
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Chapter 2. Preparation of the SRH Thioether by Bimolecular Nucleophilic Substitution  
 
The bimolecular nucleophilic substitution (SN2) is a straightforward mechanism that can be adapted for 
many purposes. As outlined in Chapter 1, past use of the SN2 has successfully generated the thioether 
bond in synthetically prepared SRH (and has similarly been utilized for thioether creation in several SRH 
analogues). As noted, however, many factors can influence the degree to which the SN2 is successful. 
Previous reports in the literature that have employed SN2 for SRH and analogue synthesis have used a 
number of different reaction conditions.40-44 In an effort to develop a focused route toward SRH synthesis 
by the SN2 method, a selection of conditions based on theory was considered before optimization. 
 
2.1 Previously Reported Generation of SRH-Related Thioethers by SN2 
SRH and many SRH-related thioethers have been synthesized by SN2 with yields ranging from 22-92%.41-
43,58,59 Reaction conditions have differed in choice of solvent (DMF,41-44,58 MeOH/water41), base identity 
(LDA,41-43 BuLi,41,44 NaOH41), and reaction time (hours,41,43,44,58 days40-43,59). Table 3 outlines past 
strategies for using SN2 to prepare the thioether bond of SRH and analogues. Given the variations in 
approach, it was deemed prudent to consider from first principles the many factors involved for the 
application of this mechanism.  
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2.1.1 Previously Reported SRH Generation 
As discussed in Chapter 1, two previous synthetic approaches have been reported for SRH. The Guillerm 
and Allart strategy (Scheme 5A) generated the partially protected tritium-labeled SRH 16 in low yield 
(22%) after heating the tritium-labeled tosylate 14 and unprotected cysteinate 15 starting components in 
DMF for 16 hours.58 Later, Zhao used a Mitsunobu-inspired approach (Scheme 5B) to produce the 
protected SRH 19a from the homocysteine thiolate generated in situ before reaction with the protected 
carbohydrate 17.59 While this method resulted in improved yields (50-70% reported), it did not provide a 
reliable synthesis in our hands.  
 
A 
 
                  14                              15                                                                     16 
 
B 
 
                 17                              18                                                                    19a 
Scheme 5. Previous synthesized protected SRH molecules58,59 (A) Guillerm and Allart generated a 
tritium-labeled SRH and (B) Zhao et al. used Mitsunobu-like coupling approach for SRH synthesis. 
 
Additionally, the required excess of the nucleophile derived from specialty chemical L,L-homocystine 
(HCySS), difficult reaction monitoring (in pyridine solvent), a long reaction time (3 d), required multistep 
deprotection, and the presence of the persistent, difficult to remove triethylphosphine oxide byproduct 
made this reaction undesirable for routine use. 
 
2.1.2 Previously Reported SRH Analogues 
Synthetic approaches towards SRH analogues have largely relied on either the aforementioned 
Mitsunobu-type coupling59 or a traditional SN2 reaction for thioether generation.41-44 Nearly all of the 
approaches reported in the literature use excess nucleophile in combination with a base of varying 
strength.40,41,43,44,59 Among these syntheses, the variety of conditions indicate no particular pattern for the 
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most effective solvent, reaction time, base, or temperature. The moderate success of couplings by Wnuk, 
Malladi, and Gopishetty (all of the same research team; Table 3, Entries 8-12) suggest that some new 
combination using a non-nucleophilic base in a convenient solvent under controlled temperature might be 
explored for the development of a revised SN2 approach.41,43,44 To facilitate a plan for investigation, some 
of the general features of the SN2 were considered. 
 
2.2 General Features of the Bimolecular Nucleophilic Substitution Mechanism 
As a generic description of the mechanism (Figure 7), the SN2 requires a lone pair of electrons on a 
nucleophilic species (Nu) to first attack the carbon adjacent (α) to a suitable leaving group. In a single 
step, the nucleophile attacks from the “back side,” opposite a leaving group, forming a new covalent bond 
as the existing bond between the carbon and the leaving group is simultaneously broken. This transition 
state is represented in central structure of Figure 7. As the leaving group is ejected, a new bond results 
between the original nucleophilic species and the carbon atom.65 
 
Figure 7. Generic SN2 reaction between a negatively charged nucleophile and neutral electrophile65 
The electrons on the nucleophile (Nu) attack the “back side” of the carbon α to the leaving group (LG). A 
new covalent bond is formed in the transition state as the existing bond to the leaving group is broken. In 
this example, the negative charge is dispersed through the transition state, and is better solvated than the 
nucleophile by aprotic, less polar solvents.  
 
Several factors contribute to both the efficacy and the rate of this reaction. The size of the nucleophilic 
atom and, if present, the formal charge on that atom are important variables contributing to nucleophilic 
strength. For example, an anion will always have greater nucleophilic character than its conjugate acid. 
Also affected by the species involved is the ease of formation of the SN2 transition state. This can be 
influenced by the sterics around the α and β positions (Figure 7) of the electrophile. If branching exists in 
either location, the transition state is established with greater difficulty, and thus negatively affects the 
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rate of reaction. Furthermore, the identity of the leaving group directly affects the rate because it is 
removed in the rate-determining step, and the ease of its departure corresponds to its stability after 
removal.66 The stability of a free leaving group is typically inverse to that species’ strength as a base. 
Some representative leaving groups are noted in Table 4, organized by their relative leaving ability.66 
Table 4. Select leaving groups ordered in decreasing leaving abilitya 
Relative Leaving Ability Leaving Group Name Structural Composition 
1 Triflate ROSO2CF3 
2 Tosylate, Mesylate ROSO2C6H4CH3, ROSO2CH3 
3 Iodide RI 
4 Bromide RBr 
5 Chloride RCl 
aAdapted from March’s Advanced Organic Chemistry66 
Additionally, choice of solvent can be very influential toward nucleophile strength. In the generation of 
SRH-related thioethers, the use of a thiolate anion nucleophile and a neutral electrophile is often 
employed. The negative charge of the nucleophile is “dispersed” through the transition state (Figure 7),66 
so use of a less polar solvent is more effective in stabilizing the transition state. In addition, aprotic 
solvents are more preferred than protic solvents in this scenario because the transition state is better 
solvated than the negatively charged nucleophile. This increased energy around the nucleophile reduces 
the needed activation energy and favors the reaction.67 
 
2.3 New SN2 Conditions for Preparing the SRH Thioether 
For the synthesis of the SRH thioether, a thiol-containing species is a logical option for use as the 
nucleophile. After the thiol is converted into a more nucleophilic thiolate anion under basic conditions, 
this thiolate could then attack a suitable electrophilic species, which upon release of the leaving group 
forms the desired thioether.65 Using this approach for SRH synthesis, compatible coupling partners could 
be prepared from accessible starting materials for use in either of two methods. SN2 method “A” (Figure 
8A) would use an amino acid derivative in the role of the nucleophile while the carbohydrate species is 
fitted with a leaving group. Reversing the roles, Figure 8B depicts SN2 method “B,” where the 
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carbohydrate derivative will act as the nucleophilic thiol in reaction with an electrophilic amino acid 
partner. Each of the methods should result in the formation of the desired protected SRH. Although to 
date method “A” has been the typical approach for this type of coupling, consideration of method “B” 
offers a potentially desirable advantage due to the steric accessibility around the carbon bearing the 
leaving group. 
 
 
A 
 
 
 
 
 
 
B 
 
Figure 8. Postulated approaches for creation of the SRH thioether bond After deprotonation by a 
base, the nucleophilic thiolate resides on either (A) the amino acid component or (B) the carbohydrate 
derivative before a substitution reaction with the appropriate coupling partner forms the thioether. 
 
In addition to nucleophilic and electrophilic roles, other variables will first be standardized for equivalent 
application to both SN2 method “A” and method “B.” As was conveyed by some of the more positive 
outcomes for past SRH-related syntheses (Table 3), the desired strategy first necessitates the use of 
alkaline conditions to drive the initial deprotonation of the thiol used for each approach (Figure 8A or 
8B). Therefore a non-nucleophilic base as well as a suitable solvent will be selected. Next, the identity of 
the leaving group that will be fixed onto either the electrophilic carbohydrate (method “A”) or amino acid 
(method “B”) will be determined. Finally, the limits of amino acid protecting groups will be tested to 
determine non-interfering protection options under these conditions. 
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2.3.1 SN2 Retrosynthesis “A”: Nucleophilic Homocysteine 
SN2 retrosynthesis “A” employs the amino acid as the nucleophile (Figure 9). With guidance from 
previous syntheses, nucleophilic derivatives can easily be synthesized from L,L-homocystine (HCySS), 
forming the desired thiol-containing HCys derivatives needed for nucleophilic coupling. 
 
Figure 9. SN2 retrosynthesis “A” Starting components are generated after standard transformations from 
HCySS and D-ribose.  
 
Protection and electrophilic activation of D-ribose produces viable electrophilic coupling partners for this 
strategy. First, a set of trials were executed to determine SN2 reaction conditions. 
 
2.3.1.1 Reaction Condition Selection: Base and Solvent* 
Initially, the reaction conditions for the SN2 thioether generation required optimization. To test for 
appropriate conditions, standard starting components were first selected. A proven stable and successful 
nucleophile under basic conditions, and capable of one step deprotection from Liu’s previous work 
(outlined in Chapter 1),60 the tert-butyl ester / Boc protected thiol 7 was prepared from HCySS. Standard 
amino acid protections were followed by tris(2-carboxyethyl)phosphine (TCEP)-mediated reduction of 
the disulfide into the respective thiol 7.41,47,68 Propyl iodide served as a sterically available electrophile 
bearing a moderately reactive leaving group.  
 
																																																								
* Investigation of these reaction conditions was performed by M. Bolitho. 
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Scheme 6. Optimization of SN2 thioether generation using a protected HCys and propyl iodide Non-
nucleophilic base KHMDS produced relative product ratio of 33 to 34 (19:1 respectively) by 1H NMR. 
 
For use in the reaction depicted in Scheme 6, a pool of non-nucleophilic bases was tested for the ability to 
facilitate this reaction with minimal disulfide byproduct formation. Consistent with past analogue 
preparations, thiol 7 was treated for 30 minutes with a candidate base at 0 oC before the electrophile was 
introduced at room temperature; the conversion of starting materials was monitored by TLC.69 THF 
served as a less polar, aprotic solvent alternative to DMF, the solvent used in a number of previously-
reported analogue preparations (see Table 3). Additionally, using THF allowed for a more expedient 
workup free from lingering residual water. After assessment of factors including reaction time and the 
ratio of formation of the desired product 33 to an unexpected oxidation byproduct 34 (yield not 
quantified, 19:1 product ratio by 1H NMR), potassium hexamethyldisilazane (KHMDS) was determined 
to be most effective base tested (data not shown) with minimal byproducts and no observed 
decomposition of starting components.69 The competing disulfide product was observed despite 
precautions used to maintain an inert atmosphere and anhydrous solvents, and the reason behind its 
formation is unknown. 
 
2.3.1.2 Electrophile Screen for Efficient Coupling 
From the starting place of the ribose component used for Zhao’s modified Mitsunobu coupling,59 only 
minor transformations were necessary to develop protected ribose derivatives 20 needed to carry out an 
electrophile screen under the newly defined SN2 reaction conditions (Scheme 7).  
NH
SH
O
O
O
O
1. base (3 equiv.), THF,
    0oC to RT, 30 min
2.
THF, RT
O
NH
O
O
O
S
NH
S
O
O 2
O
O
+
I (3 equiv.),
		 29 
 
Scheme 7. Standard conditions for use in SN2 coupling trials The tBu/Boc-protected homocysteine 
derivative 7 served as a standard nucleophile in the SN2 reaction with KHMDS in THF. Candidate 
electrophiles 20a-20b and 20d-20f were screened for reaction efficiency. 
 
Informed by species used in previously reported analogue syntheses (Table 3), the next variable 
scrutinized for this thioether generation strategy was the identification of an optimal leaving group on the 
carbohydrate moiety.41-43 A series of candidate leaving groups were considered within the relative range 
of leaving ability for groups used in similar successful thioether syntheses. Trifluoromethanesulfonyl 
(Tf), toluenesulfonyl (Ts), and methanesulfonyl (Ms) sulfonates as well as iodide (I), bromide (Br), and 
chloride (Cl) halides were chosen as candidate leaving groups to affix to the C-5 position of the protected 
ribose (Scheme 7).41-43,66 
 
All derivatives were prepared from D-ribose after standard protection to 17 (Scheme 8).70 Derivatives 20a 
and 20b were obtained as crystalline solids easily recovered in good yields (78% and 74%, respectively) 
after recrystallization from hot (~75o C) ethanol.41,71 Triflate 20c, isolated as a yellow-brown oil,72 
experienced rapid decay overnight under refrigeration.† Due to this instability, derivative 20c was 
dismissed as an impractical option for this synthesis. The halogen-bearing electrophiles 20d, 20e, and 20f 
were each prepared readily from mesylate derivative 20a using the lithium or sodium salt of the desired 
halide.73,74 Each was recovered as an oil after flash column chromatography in good yield (65 - 82%).  
 
																																																								
† The mesylate 20a decays in a similar way over an extended period of time (months) under refrigeration, while the 
tosylate 20b is stable indefinitely). 
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Scheme 8. Preparation of electrophilic ribose derivatives41,70-74 After standard protection to 17, ribose 
derivatives bearing various sulfonate and halide leaving groups at the ribose C-5 position were generated.  
 
Electrophiles 20a-20b and 20d-20f were each assessed for efficiency in both the formation of coupled 
product 19b and the absence of oxidation and elimination byproducts (34 and 26 respectively), using the 
predetermined conditions with the base KHMDS and THF as the solvent (Table 5). Examination of the 
success of each electrophile for SRH synthesis was performed by running three simultaneous trials on the 
same scale (~50 mg), using the different ribose derived electrophiles in reaction with the thiol 7.‡ 
Coupling products were monitored for completion by TLC, and characterized by 1H NMR to determine 
the relative ratios of products.  
 
 
 
 
 
 
 
 
 
 
 
 
 																																																								
‡ Coupling trial reactions performed by M. Bolitho.	
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Table 5. Electrophile screen summary under standard conditions 
 
aAll trials run on 100 mM scale of 7 in THF  bAdded as 1 M concentration in THF cDetermined by TLC (1:3 EtOAc/hexanes) as 
consumption of starting materials dYields not calculated, product ratios determined by integration of peaks in 1H NMR crude 
analysis eND = not detected 
 
The rate of SN2 coupling using the halogen derivatives varied significantly, with iodide 20f capable of 
completion within 3 h (Table 5, Entry 3) while bromide 20e progressed in >8 h (Table 5, Entry 2). Both 
the iodide and bromide trials resulted in oxidation and elimination byproduct formation (34 and 26 
respectively) in addition to the desired product 19b. Somewhat unsurprisingly, derivative 20d bearing the 
weaker chloride leaving group never reached completion after >8 h, with notable E2 elimination 
byproduct formation before the reaction was stopped (Table 5, Entry 1). Predictably, iodide 20f initially 
resulted in the most promising outcome among the halogen derivatives and was selected to run in parallel 
trials with sulfonates 20a and 20b (Table 5, Entries 4-6).  
 
Although the iodide 20f completed in a shorter reaction period (2.5 h) than the sulfonates, the ratios of 
byproducts complicated the coupling reaction and would most certainly decrease overall yield (Table 5, 
Entry 4). Mesylate derivative 20a and tosylate 20b afforded very similar coupling outcomes based on 
reaction time and product ratios, both completing within 6 h, with relatively minimal byproduct formation 
(Table 5, Entries 5 and 6). Mesylate 20a was selected in preference to the tosylate as the electrophile of 
Entrya Electrophile Electrophile 
Equivalentsb 
KHMDS 
Equivalents 
Rxn Timec 
(h) 
Product Ratiod 
(19b:34:26) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
20d 
20e 
20f 
20f 
20b 
20a 
20a 
20a 
20a 
3 
3 
3 
3 
3 
3 
2 
1 
3 
3.6 
3.6 
3.6 
2.4 
2.4 
2.4 
2.4 
2.4 
1.2 
>8 
>8 
3 
2.5 
6 
6 
7 
>8 
2 
ND:ND:1 
3:1:5 
5:1:5 
3:1:2 
6:1:ND 
7:ND:1 
1:ND:ND 
11:ND:1 
3:1:ND 
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choice for standardized SRH coupling due to its more expedient preparation. In further trials (Table 5, 
Entries 7-9) adjusting for electrophile and base equivalents, reaction conditions from Table 5, Entry 7 
were chosen for preparative scale synthesis using the mesylate 20a as the electrophile.  
 
After scaling up to a 0.5 g preparative scale with 20a as the electrophile, TLC monitoring and crude 1H 
NMR analysis showed consistent consumption of thiol 7. Isolation of the target product 19b resulted in 
reproducible modest yields of up to 47%. These results are not unlike the yields isolated from some SRH 
analogue coupling reactions using similar conditions, reagents, and the nucleophile as the limiting reagent 
(Table 3). Further, the consistency of this reaction provides a means of reliable preparation of SRH with a 
faster coupling time and improved one-step deprotection compared to Zhao’s preparation.59  
 
2.3.1.3 Protecting Group Strategy 
As demonstrated by the work of Ruoyi Liu (summarized in Chapter 1), the identity of the protecting 
groups on some homocysteine-derived coupling molecules can contribute significantly to the success or 
failure of the SN2 thioether generation.60 Using mesylate derivative 20a as the electrophile (Scheme 9), 
several variations in protection on the HCys backbone were prepared by graduate student colleague Emily 
Showell-Rouse75 and used for testing under the conditions described above (Section 2.3.1.1). Protecting 
groups were selected with the ultimate objective of one-step deprotection capability. Only two thiol 
derivatives, 22 (P1=Me, P2=Boc) and 7 (P1=tBu, P2=Boc) successfully coupled under these conditions 
with 5% and 47% percent yields, respectively. 
 
Scheme 9. Evaluation of protecting group options Several protection options were attempted to couple 
with mesylate derivative 20a under standardized conditions.  
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Several other protection combinations were tried, but resulted in decomposition or no reaction.75 The 
bulky tert-butyl ester protection (P1) for the carboxylate moiety was viewed as necessary after other esters 
(i.e., Me, Et, Bz) proved very sensitive to KHMDS under these conditions.76 Several additional carbamate 
protecting groups were also screened (i.e., Troc, Fmoc, Cbz), with only Boc-protection resulting in 
successful product formation.75 While some rationale existed for why the ester protection failed (due to 
base sensitivity), with such poor yields resulting, the carbamate protecting group strategies did not work 
well enough to warrant troubleshooting or full investigation into their failure.  
  
2.3.1.4 Summary of SRH Thioether Generation by SN2 Approach “A” 
In consideration of yield, this optimized synthesis is not an improvement over Zhao’s reported method.59 
These efforts, however, do offer a number of enhancements to SRH synthesis. First, the acid-labile 
protecting groups throughout both moieties allow for expedient global deprotection in a single step.60 
With an equal number of steps (5 conversions), as well as the coupling reaction executed in <8 h in 
comparison to three days, this coupling offers a much faster rate of preparation.69 Cost considerations of 
this synthesis are also better, with the precursor HCySS derivative used as the limiting reagent rather than 
in 3-equivalent excess used by Zhao.59 Table 6 summarizes the results of this strategy compared to those 
employed by Guillerm and Allart and those used by Zhao et al.58,59 
Table 6. Summary of synthetic routes to SRH 
 Guillerm and Allart58 Zhao59 This work 
Coupling Yield % 22 50-70  47 
Overall Yield % 5 52 26 
Reaction Time (h) 16 72 7 
Leaving Group OTs OPEt3 OMs 
Limiting Reagent electrophile electrophile nucleophile 
Deprotection steps 1 2 1 
Number of Synthetic 
Steps to Unprotected 
SRH 
8a 5 5 
aTritium labeled SRH 
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Most importantly, this synthesis provides a reliable method for SRH synthesis to use in our lab, resulting 
in very pure chemically synthesized product easy for use in biochemical assays.69 
 
2.3.2 SN2 Retrosynthesis “B”: Nucleophilic Thioribose  
The alternate SN2 strategy outlined in the following retrosynthesis (Figure 10) reverses the electrophilic 
and nucleophilic identity between the carbohydrate and amino acid components.      
 
Figure 10. SN2 retrosynthesis “B” Starting components are generated after standard transformations 
from L-aspartic acid and D-ribose.  
 
This SN2 strategy “B” theoretically has some advantages over approach “A.” First, the amino acid 
derivative bearing the leaving group “X” (Figure 10) offers less sterically hindered access for nucleophilic 
attack than the ribose derived electrophiles 20a-20f. The reduced branching around the α and β carbons 
relative to the leaving group in an L-aspartic acid-derived electrophile is proposed to improve the SN2 by 
potentially increasing the rate of reaction and/or improved yield over the SN2 approach “A” which 
employs an electrophile bearing more branching proximal to the leaving group.65 Second, the mechanistic 
competition of an E2 reaction, which was observed in approach “A,” is largely minimized due to the 
unlikely formation of a monosubstituted alkene from the activated L-homoserine electrophile.77 Finally, 
both starting components can be prepared from easily obtained and inexpensive commodity chemicals: 
the thioribose is produced from D-ribose, and the homoserine derivative from L-aspartic acid.  
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2.3.2.1 Preparation of Amino Acid Derived Electrophile  
In conjunction with efforts from undergraduate researchers Diana Cudia and Emily Murzinski, tert-butyl 
ester / Boc protected homoserine 30 was developed through synthetic Scheme 10 after appropriate 
troubleshooting.40,78-82 While it should be noted that aspartate 38 is commercially available ($258.30/5g, 
Bachem), a thorough study of the synthetic pipeline leading up to 30 was deemed critical to 
understanding what possibilities exist for the future development of SRH analogues which would require 
manipulation in the midst of these earlier chemical transformations. 
 
First, L-aspartic acid was selectively esterified with methyl protection before additional Boc carbamate 
and tert-butyl ester protection.40,78-82 No additional purification steps (apart from standard workup) were 
performed before crude aspartate derivative 37 was obtained after simple filtration. 
 
Scheme 10. Synthesis of the electrophilic homoserine40,78-82 Derivative 30 was obtained after six 
transformations from the amino acid L-aspartic acid. 
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Next, selective deprotection of the methyl ester resulted in 38, which matched the commercially available 
product analytically.78,79 This was further reduced to 39 before activation to the electrophile 30 which was 
used in the SN2 coupling reaction.81,82 Compound 30 was isolated as a white crystalline solid upon 
recrystallization from hexanes/ether and stable indefinitely under refrigeration (17% overall yield). Like 
SN2 strategy “A,” the mesylate leaving group was initially chosen for SN2 synthesis “B” for direct 
comparison on the preparative scale.81 Future introduction of other leaving groups onto homoserine 
derivative 39 remains a possibility for this synthesis.   
 
2.3.2.2 Nucleophilic Thioribose Preparation 
Thiol 31 was prepared in three chemical transformations from mesylate 20a in 66% overall yield (Scheme 
11).41,83,84 After conversion to the thioacetate intermediate 40 (72%), acetate deprotection was undergone 
to attain a mixture of the thiol derivative 31 and its oxidized disulfide (not pictured). The thiol 31 was 
purified by flash column chromatography, and the recovered disulfide was fully converted to thiol 31 
after TCEP.HCl reduction resulting in additional thiol ready for use without any further purification 
(91%). An unexpected benefit of SN2 synthetic strategy “B” was the stability of the thiol 31 under 
ambient conditions, which are not tolerated by thiols with the homocysteine backbone§. Thiol 31 
remained pure by 1H NMR, without any oxidation under typical refrigeration conditions, for greater than 
two months, while it was routinely necessary to use homocysteine derived thiols for strategy “A” within 
hours of reduction.60 
																																																								
§ After reduction, protected homocysteine derivatives began oxidative reversion into disulfide form under argon 
storage within hours or days. 
 
Scheme 11. Synthesis of the thioribose nucleophile Thiol 31 was prepared in two steps from the 
previously generated mesylate 20a in the chemical pipeline. 
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After both nucleophilic thioribose 31 and electrophilic component 30 were obtained, an initial coupling 
trial was conducted (Scheme 12) under identical conditions established in the previous SN2 strategy “A.” 
Improved yield over the SN2 strategy “A” and faster reaction time for SRH thioether generation than that 
previously reported by both us69 and Zhao59 were observed from this initial trial approach, as had been  
 
hypothesized. The true efficiency of this coupling reaction remains under consideration, though to date, 
57% yield in only 2.5 h has been acquired before optimization. This synthesis represents a potentially 
significant improvement over any of the aforementioned methods of SRH thioether synthesis. 
Furthermore, it enables SRH acquisition from easily obtained starting components and opens possible 
routes to analogue creation with modifications at the amino acid moiety. 
 
2.4 Summary, Conclusions, and Future Directions of SN2 Thioether Generation 
The investigation of the SN2 mechanism as a straightforward means to access the SRH thioether has 
enabled us to obtain SRH more consistently and conveniently (at least in our hands) than previously 
reported methods.58,59 Furthermore, the SN2 coupling strategies have supplied a solid, measureable, and 
very pure SRH salt for confident use in biochemical assays, all while returning modest yields with the 
nucleophile acting as the limiting reagent. SN2 synthetic strategy “A” provided much improved insight 
into the limitations and consistency of the SN2 method using the amino acid thiolate nucleophile. Initial 
results are encouraging for SN2 synthetic strategy “B,” although it remains an unrefined and not yet 
 
 
Scheme 12. Trial reaction of SN2 coupling strategy “B” Protected SRH 19b was successfully prepared 
in a trial reaction with modest yield and improved reaction time.   
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replicated approach using the carbohydrate component as the nucleophile for the first time. The 
opportunity for optimization of strategy “B” is an option for further research, while the benefits of 
improved reaction time and modest gains in yield are already apparent.  
 
The background research for strategy “B,” particularly in cultivation of the electrophilic homoserine 
derivative, allowed for greater understanding for possible syntheses involving the introduction of 
modifications onto an electrophilic amino acid analogue. One generic design (Figure 11), which will be 
discussed further in the following chapter, would introduce one or more substituents onto the C-3 position 
of the amino acid (β). 
 
Figure 11. Postulated amino acid electrophile for analogue synthesis Introduction of a substituent 
onto the C-3 position of the amino acid component before SN2 coupling could lead to a series of 
analogues modified on the HCys moiety. 
 
Limits on the structure of this derivative would undoubtedly be imposed by the conditions of involved in 
the synthetic plan and the conditions required for coupling (namely the alkaline environment). Steric 
considerations at the position β to the leaving group may also be of concern if the substituent introduced 
is too bulky for efficient SN2 coupling. 
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Chapter 3: Preparation of the SRH Thioether Bond by Thiol-Ene Coupling 
 
While the SN2 strategies for SRH preparation have resulted in consistent output of the target molecule, 
they have not yet fulfilled the concurrent goal of improving yield. As noted, there is still potential for 
optimizing the SN2, and further trials remain enticing particularly for approach “B”. We must also 
acknowledge that SN2 conditions may not always be a viable option for thioether generation in the context 
of SRH analogue creation. The goals of improving yield and eventually generating a large number of 
SRH analogues for inhibition studies motivate the consideration of as many coupling options as feasible. 
Benefits of the thiol-ene coupling include its track record as an inexpensive, quick, and robust reaction, 
often high-yielding, and resilient to ambient conditions.61,62 This chapter will detail the investigation into 
TEC as a mechanism for thioether creation in SRH. 
 
3.1 Previously-Reported TEC Preparations of Thioether Bonds in Small Biomolecules 
The radical-induced TEC reaction was considered for synthesis of SRH due to its record as a versatile and 
expedient method. In addition to countless applications within synthetic polymer chemistry and other 
fields, the TEC reaction has been adapted to the synthesis of several biologically-related molecules.85 
Research performed by Fiore and coworkers has successfully demonstrated well-optimized use of the 
TEC reaction for consistent formation of thioether bonds between various carbohydrate and amino acid 
derivatives (Scheme 13).63,64 
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Scheme 13. Groundwork TEC reactions by Fiore and coworkers63,64 (A) Protected carbohydrates bond 
by TEC mechanism to form an S-glycoside. (B) Fiore cites steric reasons for the formation of a single 
stereoisomer. (C) Carbohydrate and amino acid partners are coupled by TEC. 
 
Interested in forming S-glycoside bonds between sugars, work reported by Fiore et al. first created a 
number of thioethers between various protected sugars using a catalytic amount of the radical initiator 
2,2-dimethoxy-2-phenylacetophenone (DPAP) in a solution of methylene chloride at room temperature 
and exposure to UV radiation at 365 nm.63 These derivatives included the use of alkene-containing 
erythrofuranoside 26 (Scheme 13A), which was coupled with glucose derivative 25 to form thioether 
linkages in high yield (92%), and resulted in the reported formation of product 27 containing the same 
ribofuranoside moiety sought for SRH synthesis. Reillustrated in Scheme 13B is the description by Fiore 
and coworkers for the stereochemical preference at the newly formed chiral center in derivative 27 which 
results after the propagation step of the reaction.63 The authors note that “these intermediates expose the 
less hindered face to a molecule of thiol from which they abstract a H! radical in the final and irreversible 
locking step.”  
 
Similarly, the same mild reaction conditions were later applied by Fiore and coworkers for S-glycopeptide 
bond formation between carbohydrate and amino acid moieties.64 Scheme 13C illustrates this method 
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whereby a protected vinyl glycine derivative 28 was used, which after coupling with glucose derivative 
25, results in the formation of product 29 bearing the homocysteine moiety desired in SRH synthesis. 
This reaction also proceeded with good yield (90%) and a brief reaction time (30 min). These synthetic 
outcomes largely outlined the groundwork for adaptation of TEC for SRH synthesis. Before trials of this 
method were performed, however, a better understanding of the TEC mechanism was garnered for shrewd 
application. 
 
3.2 General Features of the TEC Mechanism 
The TEC mechanism results in anti-Markovnikov addition between thiol and alkene substituents by 
hydrothiolation of the double bond.61 Employing this reaction by radical mechanism (Figure 12), an 
initiating radical abstracts the hydrogen from a thiol, producing a thiyl radical about the sulfur atom. The 
thiyl radical then steals an electron from the double bond of the alkene, binding the two components by 
anti-Markovnikov addition onto the double bond as the radical stabilizes on the adjacent secondary or 
tertiary carbon atom.  
 
Figure 12. Generic TEC reaction by radical mechanism An initiating radical activates a thiol 
molecule. This bonds with available alkenes in an anti-Markovnikov addition. The reaction propagates 
when a hydrogen is abstracted from a new thiol molecule and the thioether is created. 
 
The new thioether is finalized when the carbon-centered radical abstracts a hydrogen atom from a new 
thiol molecule, simultaneously activating a new thiyl radical and propagating the chain reaction. The 
reaction eventually terminates with any of the typical termination combinations for radical reactions.86  
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3.2.1 Conditions Used in TEC Reactions 
Radical reactions are by their nature reactive with a need for only low catalytic initiator concentration for 
the chain reaction to progress.87 Just as specifics surrounding the SN2 coupling were involved in the 
success or failure of those reactions, several factors can affect a TEC reaction. While the particular 
conditions used for TEC reactions are important, they do not theoretically play as significant a role as the 
identity of the reactants themselves. TEC is generally tolerant to water and air exposure so long as their 
concentration(s) are much less than the thiol used (disulfide byproducts from the homocoupling of the 
thiol may be observed in these reactions).61 Solvent effects are also limited; while polar solvents can 
affect the reaction due to hydrogen bonding, thiols are generally poor hydrogen bonders, and these effects 
are more often observed in situations using particular classes of reactants.86 
 
While TEC methods using either no catalyst or a base/nucleophile mechanism exist, problems 
surrounding the use of protecting groups under alkaline conditions that we had previously observed (see 
section 1.3.2) combined with the demonstrated ease of the radical mechanism prompted no apparent 
benefit in exploring these as options for this synthesis.61 
 
3.2.1.1 Reaction Effects from the Alkene Substituent 
Many types of alkenes can successfully undergo TEC, even substituted olefins which could be useful in 
future SRH analogue development. 61 There can be substantial differences, however, in the coupling 
results. Much variation in reactivity and rate is due to the olefin, which is subject to steric effects as well 
as the nature of the double bond itself.61,86 Terminal alkenes are generally more reactive than internal 
substituted olefins for steric reasons. Reactivity generally decreases directly with reduced electron density 
of the double bond; this is correlated to the structural positioning of other functional groups around the 
alkene. Bond angle stability and intermediate radical stability also play a significant role in whether the 
reaction will progress.61  
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TEC reactions are also reversible, as often observed with the use of alkenes having internal cis-double 
bonds, which may isomerize into the trans- isomer.61,86 While target cis-products can still be made, the 
yields are affected by the competing trans-cis equilibrium.61 Another structural effect of the alkene on the 
reaction can come from heteroatom placement when situated at vinylic or allylic positions, leading to 
fragmentation or altered regioselectivity. 86 
 
3.2.1.2 Reactivity of the Thiol Substituent 
The structure of the thiol can also influence the reaction, though the reasons are not as well studied as 
their alkene partners. Thiyl radicals can form from an initiator radical, light or heat, or one-electron 
oxidants. The formation of the radical is dependent on the bond dissociation energy of that particular 
thiol, and whether or not the reaction proceeds is based upon its thermodynamic feasibility.86 It is also 
believed that polar effects and hydrogen bonding may influence the reactivity of the thiol in certain 
scenarios.61  
 
3.3 Identification of TEC Strategies for Preparation of the SRH Thioether 
Like the SN2 strategy, two obvious possibilities are available for the application of this mechanism for 
SRH synthesis. In either scenario, the carbohydrate or amino acid component contains the alkene 
functional group complemented by the thiol on the opposite coupling partner. “TEC method A” (Figure 
13A) starts with the same type of protected HCys thiol used in the “SN2 method A.” In this mechanism, 
however, an initiating radical abstracts the hydrogen from the thiol to form a thiyl radical on the HCys 
component. This progresses with the thiyl coupling onto an olefin-containing erythrofuranoside 
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A 
 
 
 
 
 
B 
 
Figure 13. TEC strategies for SRH synthesis The desired thioether could be generated in a 
protected SRH molecule using the TEC mechanism by either of two accessible strategies. (A) A 
HCys derivative couples with a carbohydrate bearing an alkene group. (B) Protected vinylglycine 
bonds an available thioribose. 
 
derivative. The reaction is propagated when the radical, now on the tertiary center of the carbohydrate 
moiety, abstracts a hydrogen from another protected HCys and secures the formation of the new 
stereocenter (as modeled by Fiore et al. (Scheme 13B)) on the protected SRH molecule. 63  
 
The TEC strategy also has the option of method “B” (Figure 13B), beginning with the same resilient 
thioribose used in “SN2 method B.” After hydrogen abstraction, the radical bonds with a protected vinyl 
glycine similar to the derivative used by Fiore et al. (Scheme 13C). The reaction propagates onto another 
thioribose, but in this scenario, there is no formation of a new stereocenter as the desired chiral structure 
is already in place in the existing thioribose.  
 
Success of either of these strategies with application to SRH synthesis could also provide mild conditions 
suitable for analogue preparation, particularly in situations when a SN2 mechanism may not be effective 
in joining the requisite sugar and amino acid moieties. 
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3.4 TEC Retrosynthesis “A”: Carbohydrate as the Alkene Substituent  
As previously outlined, the proposed retrosynthesis for the preparation of the SRH thioether using the 
TEC approach “A” is shown in Figure 14. Fiore et al. used the molecule 26 and suggested exclusive 
formation of coupling products with desired stereochemistry about the newly formed stereocenter. Based 
on Fiore’s reported outcome, derivative 26 could be used in conjunction with a protected HCys to 
generate a fully protected SRH by TEC.63 
 
Figure 14. Retrosynthetic construction of the SRH thioether using TEC method “A” Components 
may be synthesized after standard conversions of commercially available molecules D-ribose and HCySS. 
 
The alkene 26 may be produced from products 20a or 20b derived from D-ribose. Like the SN2 strategy 
“A”, the HCys derivative 22 was prepared after reduction from the corresponding protected HCySS. 
 
3.4.1 Generation of the Erythrofuranoside Olefin 
After consideration of the synthesis pipeline for previously generated ribose derivatives (Scheme 8, 
Chapter 2), the alkene 26 was prepared with only one additional conversion via an elimination reaction 
(Scheme 14).  
 
Scheme 14. Synthesis of the alkene-containing erythrofuranoside derivative Using an elimination 
reaction on existing ribose derivatives generates the desired alkene.  
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Using either ribose derivative 20a or 20b, the target molecule was obtained by reaction with potassium 
tert-butoxide (tBuOK) in THF.88 Similar yields resulted from use of either starting material after the 
product was purified by silica gel flash column chromatography and isolated as an oil. 
 
3.4.2 TEC Strategy “A” for the Synthesis of SRH 
Similar to the protected homocysteine derivative 7 used in Chapter 2, the methyl ester / Boc protected 
thiol 22 was synthesized from HCySS using standard protection and TCEP-mediated reduction of the 
preceding disulfide.40,41 Together with compound 26, thiol 22 was coupled by the TEC radical mechanism 
under conditions adapted from Fiore et al.63 Using a substoichiometric amount of DPAP (10 mol% of 
thiol concentration) to generate an initiating methyl radical,89 the starting components were mixed in a 
solution of anhydrous methylene chloride and irradiated at 365 nm (Scheme 15). 
 
             22          26                  19a 
 
Scheme 15. Anticipated protected SRH synthesis by TEC Based on theoretical representations by 
Fiore and coworkers, desired compound 19a was sought by reaction components 22 and 26. 
 
As anticipated, the coupling product in this reaction existed with formation of a single stereoisomer 
isolated after flash column chromatography. Based on outcomes of TEC coupling reactions reported by 
Fiore et al., HCys component 22 and ribose derivative 26 were predicted to generate the thioether bond in 
protected SRH 19a with the appropriate stereochemistry at the neighboring asymmetric carbon (Scheme 
15). Surprisingly, 1H NMR indicated a product that differed from previously-synthesized protected SRH 
derivative 19a (Scheme 16A) generated by SN2 coupling.  
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A 
 
                22                          20a                                                          19a 
 
 
B 
 
               22                           26                                                             41 
 
Scheme 16. Synthesis of protected SRH and diastereomer (A) The protected SRH derivative 
was produced by SN2 coupling outlined in Chapter Two. (B) Postulated formation of the SRH-
like diastereomer by TEC coupling. 
 
These differences were apparent in significant shift and splitting patterns of the peaks representing 
hydrogen atoms adjacent to and directly at the newly formed chiral center on the ribose moiety. With two 
possible stereochemical outcomes in the product, it was postulated that initial trials of this reaction 
resulted in the exclusive creation of the L-lyxofuranoside-containing diastereomer 41 exhibiting a 
difference about that newly formed stereocenter (Scheme 16B). This reaction nonetheless progressed with 
moderately good yield, >68%, proceeding with notable improvement over SN2 couplings.  
 
3.4.2.1 Definitive Identification of Major Product as the SRH-like Diastereomer 
Careful analysis of 1D and 2D 1H NMR spectra was conducted in order to definitively characterize the 
isolated product from this synthesis as diastereomer 41. The primary difference between the two possible 
coupling products can be observed in changes to those 1H NMR peaks representing hydrogen atoms 
around the newly formed stereocenter (Figure 15). 
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B 
 
Figure 15. 1H NMR spectra of key hydrogen peaks in SRH and diastereomer Spectra in 
the range of 2.5 – 4.8 ppm inclusive of key shifts and splitting patterns in SRH and 
diastereomer derivatives.  
 
Peaks in the range between 2.5 and 4.8 ppm from 1H NMR analysis of compound 19a previously 
synthesized by SN2 (Figure 15A) and the postulated diastereomer (Figure 15B) were considered. Verified 
by the reported NMR analysis of the same compound by Albiniak, protected SRH derivative 19a 
produces doublets at δ 4.69 ppm and 4.60 ppm (Figure 15A) representing hydrogen atoms at positions 3 
and 2 respectively.70 These neighboring protons split each other with a J-value of 6.0 Hz. Indeed this 
coupling constant relationship is maintained throughout many ribose-derived molecules; compounds 20a-
20f, 26, 31, and 40 all produce 1H NMR peaks for hydrogen atoms 3 and 2 as doublets, with coupling 
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constants in the range of J = 5.8 - 6.0 Hz. Furthermore hydrogen 4 on derivative 19a produces a doublet-
doublet at δ 4.23 ppm (Figure 15A), which 2D analysis (see supporting information) by COSy NMR 
indicates is a result of splitting between H-4 and hydrogen atoms 5a and 5b (δ 2.75 ppm and δ 2.59 ppm), 
with coupling constants of J = 9.5, J = 6.2 Hz.  
 
Analysis for the newly formed isomer 41 indicates notable deviations from these patterns (Figure 15B). 
While the coupling relationship between hydrogen atoms 2 and 3 on the diastereomer are maintained (J = 
5.9 Hz), the hydrogen at position 3 (δ 4.71 ppm) now splits as a doublet-doublet, with the additional 
coupling constant J = 3.6 Hz. COSy analysis indicates that hydrogen 3 is now interacting with hydrogen 4 
in addition to hydrogen 2. The splitting pattern of hydrogen atom 4 (δ 4.05 ppm) also reflects this 
relationship, now producing a triplet-doublet with additional interactions between both hydrogen atoms at 
position 5 (δ 2.78 – 2.87 ppm) and now hydrogen atom 3. 
 
Interestingly, the same pattern for those proton peaks in diastereomer 41 can be observed in the reported 
1H NMR spectrum (not shown) of Fiore’s compound 27.63 Namely, hydrogen atoms at positions 2 and 3 
split each other with a coupling constant J = 5.9 Hz, and also like diastereomer 41, hydrogen 3 also splits 
hydrogen atom 4 (J = 3.6 Hz). Summarized in Table 7 is the coupling relationship between these key 
peaks. 
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Table 7. Representative 1H NMR peak splitting of SRH and related compounds63,70 
Compound J 2,3 J 3,4 
 
 
19a 
 
6.0 Hz 
 
No interaction 
 
 
41 
 
5.9 Hz 
 
3.6 Hz 
 
 
27 
 
5.9 Hz 
 
3.6 Hz 
  
While additional coupling constant evidence was at times unclear due to peak overlap or indistinct peak 
splitting, evidence of these spatial relationships was noted in observation of COSy 1H NMR spectra (see 
supporting information). 
 
3.4.2.2 Three Dimensional Modeling of SRH Diastereomers 
With this information, it is proposed that the model described by Fiore et al.,63 involving the final 
irreversible step of hydrogen abstraction by the carbon-centered radical, indicated the opposite 
stereochemistry around the newly formed chiral center than what was actually produced. Modeling the 
SRH and diastereomer structures on Spartan, using the PM3 method, the calculated dihedral angle 
between hydrogen atoms 3 and 4 was found to be -114.78o for the SRH derivative 19a and 24.84o for the 
diastereomer 41. A traditional Karplus-type calculation is not available for five-membered rings, having 
coupling constants that are difficult to diagnose.90 Though generic calculators exist for calculating 
coupling constants in furanose sugars,91 their characterization is complicated by pseudorotational 
variation,92 and no supporting data was found in the literature enabling us to infer J-values for structures 
having the skeleton of the two diastereomers presented.  
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As Fiore correctly argues, however, the hydrogen should be abstracted and form the new chiral center 
from the less sterically hindered side.63 Figure 16 depicts the skeletal structure of the intermediate 
molecule; after the joining of the C-S bond, the radical would be centered on the indicated carbon. While  
 
Figure 16. Three-dimensional model of radical intermediate With the radical stabilized on the tertiary 
carbon (blue arrow), abstraction of a hydrogen to complete the thioether could occur from either the front 
or reverse side. The acetonide (bottom left) could hinder abstraction on that side, leading to the preferred 
outcome of diastereomer 41. 
 
the three-dimensional model does not provide a calculated coupling constant, it does model a concave 
shape due to the bulky acetonide protection. This could hinder the propagating hydrogen abstraction from 
that side and favor formation of the L-lyxofuranoside moiety instead of the D-ribofuranoside found in 
SRH. 
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3.4.3 Summary of TEC Coupling Strategy “A” 
Compared to both SN2 strategies previously attempted, the coupling components using TEC method “A” 
bonded by the TEC mechanism with improved reaction time (2 h) and overall yield (>68%), although the 
resulting product was exclusive formation of diastereomer 41. The reason for this deviation from the 
expected outcome is uncertain. Knowledge of steric influences on radical reactions and the 3D spatial 
relationship around the new stereocenter of the molecule from the acetonide protection strongly support 
the claim that the final hydrogen abstraction step would favor the L-lyxofuranoside-containing structure. 
Other possible steric influences might prevent the final step from occurring for the same reason, such as 
hindrance from the thiol coupling partner, though similarities from the coupling of Fiore’s compound 27 
provide at least one example that the trend does not change with a varied thiol.63 
 
Confident in the analysis of coupling product 41 and pleased with the good initial yield and purity after 
employment of the TEC mechanism in this context, the preparation of the SRH thioether with correct 
stereochemistry was pursued by TEC strategy “B.” 
 
3.5 TEC Retrosynthesis “B”: Vinylglycine as the Alkene Substituent 
The final SRH synthetic strategy considered was use of the TEC method “B” using a vinyl glycine 
derivative and the thiol again positioned on the ribose moiety. The possibility of the undesired 
stereoselective outcome should be resolved with this strategy, as the alkene terminates at a secondary 
carbon on the vinyl group of amino acid component, and the appropriate SRH stereocenter is 
predetermined in thioribose (Figure 17). 
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Figure 17. Retrosynthetic construction of the SRH thioether using the TEC method “B” 
Components may be synthesized after standard conversions of commercially available molecules D-ribose 
and L-aspartic acid. 
 
As previously generated for use in SN2 strategy “B,” the thioribose derivative was obtained from D-ribose. 
The vinyl glycine was procured from the pipeline of molecules previously acquired for the SN2 
mechanism starting from L-aspartic acid. 
 
3.5.1 Preparation of Vinyl Glycine by Grieco Elimination 
Aiming to generate the vinyl glycine derivative 32 from an amino acid derivative in the existing chemical 
pipeline, synthetic routes were examined from starting compound 38 or 39. Building off of one of these 
derivatives would allow for limited additional synthetic steps, leave open the possibility for adding 
substituents for future analogue development at earlier precursor stages, and again start from the 
inexpensive amino acid L-aspartic acid.  
 
Though Fiore et al. utilized alternate amino acid protection in their trials,64 the mild conditions of the TEC 
mechanism indicated no foreseeable complication with tert-butyl ester and Boc protection. Additionally, 
maintaining these same protecting groups allowed for direct comparison of synthetic outcomes obtained 
from the SN2 coupling trials. Siebum et al. has conveniently developed a method for vinyl glycine 
synthesis compatible with tert-butyl and Boc protection.93 Using the “Grieco elimination” shown in 
Scheme 17, the target molecule 32 was prepared from protected homoserine 39 in two transformations 
(52% overall). First, activation to the selenide 42 was accomplished using 2-nitrophenyl selenocyanate 
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and tributylphosphine (72%). After purification, 42 underwent elimination upon treatment with 30% 
hydrogen peroxide to generate the target molecule 32 (72%). 
 
     39                    42        32 
Scheme 17. Synthesis of a protected vinyl glycine derivative93 From homoserine derivative 39, Grieco 
elimination was employed to form the desired vinyl glycine 32. 
 
A trial of the first reaction in this sequence was executed, but 1H NMR analysis and purification by flash 
column chromatography were greatly complicated by the overwhelming presence of excess selenium and 
phosphine reactants and byproducts. After having been placed aside for extended time (greater than three 
months under refrigeration), the crude residue was later purified successfully by flash column 
chromatography using a different mobile phase. Subsequent extensive 1H NMR analysis of the isolated 
material indicated that the reaction intended to produce intermediate 42 had spontaneously continued, 
completing the second step of Scheme 17 and resulting in production of the target molecule 32, with 27% 
yield.  
 
Whether extended time in refrigeration or some unknown reaction influenced the formation of the final 
product, this inspired the possibility of a one pot sequence of the reactions outlined in Scheme 17, which 
has been successfully accomplished in similar Grieco elimination models in published literature.94 After 
resulting in a poor yield (<29%) after a single trial using the one pot synthesis, the selenide intermediate 
42 was again synthesized with better knowledge of the complexity of the purification. The selenide was 
isolated after flash column chromatography and was subjected to treatment with hydrogen peroxide in 
THF. This trial resulted in an improved yield (52% over two steps), with product identity and purity of 32 
confirmed by 1H NMR analysis. 
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3.5.2 Preparation of D-Thioribose Derivative  
Having utilized the thioribose 31 in the SN2 strategy “B,” further preparations of this molecule were 
obtained with ease. Again, this synthesis proved convenient with the extended stability observed with the 
thioribose when compared to other more oxidation susceptible thiols presented earlier. 
 
3.5.3 Formal Synthesis of SRH by TEC 
With verified vinyl glycine 32 and D-thioribose 31 components, the alternate radical coupling strategy 
was assessed for potential use for SRH synthesis using conditions similar to those set by Fiore and 
coworkers.63,64 The results of several coupling trials are summarized in Table 8. The initial trial of this 
reaction (Table 8, Entry 1) used 1.2 equivalents of the thiol and an initial addition of approximately 9 
mol% DPAP initiator. After isolation of the product by flash column chromatography, Trial 1 resulted in 
disappointing yield (29.8%), although the correct diastereomer 19b was successfully produced by this 
TEC strategy. A significant amount of the disulfide 43 resulting from homocoupling of 31 was also 
isolated from the column purification in addition to unreacted 32. 
 
Table 8. Optimization of SRH thioether generation by TEC 
 
  
 
 
 
aAdded intermittently in doses bUV radiation turned off for O/N stir   
 
Entry Equivalents 
of Thiol 
Concentration 
Thiol (M) 
Mol% of 
thiol 
Rxn Time 
(h) 
Yield  
(%) 
1 1.2 0.07 34.1a 23.75b 29.8 
2 3.0 0.5 22.5a 4.33 88.2 
3 2.9 0.5 25 1.50 93.2 
4 2.0 0.5 25 1.50 89.5 
5 2.0 0.5 15 1.50 87.5 
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Additionally, similar to what was observed in some early trials of TEC strategy “A,” monitoring of the 
reaction indicated very quick formation of product (within ~30 min), suggesting a good initial reaction 
rate. The reaction progression seemed to plateau, however, after hours of TLC monitoring. The radical 
mechanism being catalytic, it was unknown why this appeared to be occurring, and additional aliquots of 
DPAP were added intermittently to the reaction (Table 8, Entries 1 and 2) until consumption of the 
limiting reactant 32 was observed by TLC.  
 
Due to the poor yield of the first trial, improvements were considered from an earlier publication by 
Dondoni.62 His work presented results indicating potential contributors to poor yields, specifically, initial 
thiol concentration, thiol equivalents, and the amount of DPAP used. Each of these variables was adjusted 
to be consistent with the optimized conditions Dondoni used in this synthesis (Table 8, Entry 2). Using 
three equivalents of the thiol 31 in a significantly higher concentration (0.5 M) resulted in much improved 
results (88.2 % yield) over the first trial, though the initial addition of 13.7 mol% DPAP still prompted the 
necessity for additional aliquots to be added throughout the reaction.  
 
Trial 3 adjusted this initial DPAP concentration to a one time initial addition of 25 mol%. This resulted in 
extremely encouraging results of 93% isolated product yield after flash column chromatography. 
Additionally, the reaction was complete in just 1.5 h, providing much improvement over past syntheses. 
Despite the literature indicating the success of TEC reactions under exposure to ambient conditions, flame 
dried equipment and anhydrous solvent was used under an argon atmosphere. Even so, formation of 
disulfide 43 was still observed in all trials. While excess thiol is deemed necessary to accommodate for 
disulfide conversion, the isolation of less than one equivalent of disulfide byproduct from trial 3 prompted 
the testing of this reaction using two equivalents of the thiol (Table 8, Entry 4). The use of two 
equivalents resulted in comparable yield (89.5%) in the same reaction time as the previous trial. Lastly, 
entry 5 reduced the amount of photoinitiator to 15 mol% and two equivalents of thiol. The resulting yield 
was reduced (87.5%), although isolation of the product was still favorable. 
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The optimization of this strategy represents a clear enhancement over any of the previously attempted 
SRH coupling reactions. The improved reaction time, mild conditions, coupling yield, preparation of 
components from accessible commodity chemicals, stability of the necessary thiol, and the possibility of 
use in analogue development are all extremely notable attributes to this synthesis. 
 
3.6 Summary and Future Directions 
SRH synthesis was reexamined by testing four strategies for thioether generation using two different 
mechanisms. Both the SN2 and TEC methods can be further optimized for better results and insight into 
the possibilities and limitations of the chemical synthesis of SRH. In further refining the methods studied 
in this thesis, some important additional steps could be completed. With the relative success of the TEC 
strategy “B,” this reaction has not yet been performed at a preparative scale. To best complete the goal of 
obtaining larger amounts of SRH used for testing in the Ellman’s Assay, this should be a priority moving 
forward. Additionally, the components needed for TEC strategy “B,” the thioribose 31 and vinylglycine 
32, have been isolated with moderate yields and could be improved on. Other more fundamental variables 
have also not yet been tested, such as solvent identity in the TEC coupling, use of a different radical 
initiator, or protecting group selection. The SN2 coupling should also be further studied. Full consumption 
of the starting materials is consistently observed, and yet after purification, only moderate yields are 
isolated. SN2 strategy “B” has not yet been replicated, and improved results over SN2 strategy “A” suggest 
it could be a valuable synthesis moving forward after optimization, particularly for use in analogue 
development. Although optimization of either the SN2 or TEC mechanism for SRH synthesis may be still 
be refined, the described trials have established a good framework and understanding for generating the 
thioether bond of SRH with acceptable yields of a pure, solid, and stable target molecule.  
 
Moving forward, attention should also turn to the synthesis of SRH analogues. A number of design 
possibilities exist for analogue structures that could be developed and tested for inhibitory activity against 
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LuxS. Identification of target molecules have included the design of an analogue with the addition of any 
number of changes at the homocysteine C-3 position (Figure 18).  
 
Figure 18. Target SRH analogue with modification at the HCys C-3 position A novel approach to 
SRH analogue preparation, modification on the HCys moiety could allow for competitive active site 
binding while disrupting enzyme activity. 
 
This strategy has not been considered in the literature for SRH analogues, as Zhao59 verified the 
importance of the amino acid moiety for enzyme activity, and Pei modeled the action of DPD production 
facilitated on the ribose moiety. Introducing a small structural change in the homocysteine moiety at the 
C-3 position, however, could result in an inhibitory mechanism whereby the inhibitor could tightly bond 
with key residues in the LuxS active site while disrupting the three-dimensional positioning of catalytic 
factors needed to catabolize the ribose moiety into DPD. Although not directly interfering with the 
identity of the carbohydrate moiety acted upon by Pei’s mechanism,46 disrupting the positioning of the 
enzyme’s spatial relationship to these functional groups on SRH could compete for the enzyme’s active 
site while inhibiting its activity.60 
 
3.6.1 Proposed Synthesis for an Alkylated Vinyl Glycine Suitable for TEC Coupling  
Considering either of the mechanisms for thioether generation in SRH, there are available strategies for 
creating a methylated analogue that could be employed for each synthetic route. Application of a Julia- 
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Figure 19. Postulated generation of an alkylated olefin95 Applying the method by Aïssa to L-
threonine could be a convenient synthesis for an alkylated olefin for use in TEC. 
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Kocienski conversion onto a different commodity amino acid, L-threonine, after standard protection, 
could result in generation of a desired alkylated olefin (Figure 19). Aïssa has evaluated this mechanism 
for robust application,95 creating many alkene-containing products by conversion of the carbonyl with the 
use of the reagent 1-tert-butyl-1H-tetrazol-5-ylmethyl sulfone, which can be easily generated from tert-
butyl isothiocyanate. This procedure has been demonstrated as compatible with ester and carbamate 
protecting groups, and results in good reported yields of various products.  
 
3.6.2 Proposed Synthesis for an Alkylated Homoserine Derivative for SN2 Coupling 
For use in a SN2 approach, alkyl-substituted aspartates have been successfully prepared by Burtin et al. 
(Scheme 18).96 After conversion of protected aspartate 38 into the lactone 44, alkyl substitution can occur 
at the original C-3 position, resulting in mono-substituted diastereomers or the di-substituted product.  
 
Undergraduate researcher Diana Cudia has replicated one method used by Burtin et al. through the step 
introducing the alkyl substituent(s), although recovered yield was extremely low (2%) and resulted as a 
mixture of the possible products 45a-45c.78,96 Isolation by chromatography is also a challenging factor 
until this reaction step can be optimized for improved conversion to the target molecule(s).  Ideally  
the cyclization could then be reversed followed by a reduction reaction and the introduction of a leaving 
group (i.e., mesylate). This method could result in the formation of any of the three possible analogues.  
 
 
 
        
           38                                                     44                                   45a (R1=H, R2=Me)                          46a (R1=H, R2=Me) 
                                                                                                             45b (R1=Me, R2=H)                          46b (R1=Me, R2=H) 
                                                                                                             45c (R1=Me, R2=Me)                        46c (R1=Me, R2=Me) 
 
Scheme 18. Projected synthesis of alkylated aspartate for conversion to SN2 electrophile Alkylation 
demonstrated by Burtin et al. could lead to up to three protected aspartate derivatives. Cudia has 
successfully reproduced 44 and 45 in 50% and 2% yield respectively. 
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3.6.3. Additional LuxS Inhibition Targets 
An interesting analogue examination could be to deprotect the erroneously generated SRH diastereomer 
to derivative 41 into 47 (Figure 20A), and test it against SRH for inhibitory action on LuxS. Wnuk 
created a xylofuranose analogue (Figure 20B), differing from SRH only in stereochemistry of the 
carbohydrate.41 When tested, this analogue resulted in moderate inhibition of LuxS (KI = 4.2 +/- 1.2 µM). 
 
A 
 
 
                                       41                                                                              47 
 
B 
 
S-(5-deoxy-D-xylofuranos-5-yl)-L-homocysteine 
 
Figure 20. Analogues containing alternate furanose sugars (A) Deprotection of the SRH diastereomer 
and (B) xylosyl analogue prepared by Wnuk et al. offer isomeric options for competitive inhibition of 
LuxS.41 
 
This also prompted the idea of synthesizing some additional analogues varying in the carbohydrate 
moiety. Generation of a thiol derivative after standard protection of commodity sugars may be an easy-to-
access route for a set of analogues in addition to Wnuk’s xylosyl derivative and the L-lyxose diastereomer 
prepared in this thesis.41 The possibility may also exist to recreate the xylosyl derivative with the ease of 
the TEC reaction through a possibly less tedious method. 
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Experimental 
 
 
 
Methods  
 
All glassware was flame- or oven-dried, and reactions were performed under an argon atmosphere unless 
noted otherwise. Reagents were purchased from vendors at reagent grade or higher purity. Ethyl acetate 
(EtOAc), hexanes, dioxane, dimethylformamide (DMF), ethanol (EtOH), triethylamine (TEA), toluene 
(PhMe), methanol (MeOH), and acetone solvents were purchased dry from commercial vendors. 
Anhydrous dichloromethane (CH2Cl2), tetrahydrofuran (THF), and diethyl ether (ether) were dispensed 
from a Glass Contour Solvent Purification System (SG Waters). Notable reagents used were L,L-
homocystine (Bachem), tris(2-carboxyethyl)phosphine hydrochloride (TCEP.HCl, Amresco), potassium 
hexamethyldisilazane (KHMDS, 15% w/w in toluene, Alfa Aesar), and 2,2-dimethoxy-2-
phenylacetophenone (DPAP). Thin layer chromatography (TLC) monitoring was performed using Silica 
G plates (SORBENT Technologies) with UV254, and unless otherwise stated, used with a potassium 
permanganate (KMnO4) stain. Target molecules were purified using flash column chromatography with 
60Å, 230-400 mesh silica gel (SORBENT Technologies). Solvents were removed by rotary evaporation 
(Buchi R-114, Welch DirecTorr pump) and high vacuum oil pump. NMR analysis was performed on a 
VNMRS spectrometer (Agilent) with an oneNMR probe (500MHz for 1H, 125 MHz 13C) and spectra 
were processed on Mnova software (Mestrelab) with residual solvent references of CDCl3 at 7.26 ppm 
(1H) and 77.16 ppm (13C). FTIR spectra were acquired on a Spectrum 100 FTIR spectrometer (Perkin 
Elmer). Melting points were found using a Stuart SMP10. High-resolution mass spectrometry (ESI-
HRMS) analysis was performed by the Scripps Research Institute Center for Mass Spectrometry in La 
Jolla, CA. 
 
 
 
Chemical Synthesis Procedures 
 
General procedure for TCEP-mediated reductions 
Modification of published procedure.41 To an approximately 100 mM solution of disulfide in DMF was 
added an approximately 700 mM solution of tris(2-carboxyethyl)phosphine hydrochloride (TCEP.HCl) in 
ddH2O in one portion at room temperature. The reaction was monitored for consumption of starting 
material by TLC (1:3 EtOAc/hexanes) after stirring overnight at room temperature. The reaction mixture 
was poured onto brine (100 mL), and the product was extracted with one portion of diethyl ether (100 
mL) then with three portions of diethyl ether (50 mL). Each organic layer was washed individually with 
four portions of water (75 mL). The organic layers were then combined and washed with a single portion 
of brine (100 mL) and dried over magnesium sulfate. After filtration, bulk solvent was removed via rotary 
evaporation and trace solvent was removed by high vacuum to constant mass. The desired thiol was 
stored with refrigeration under argon and typically used within 24 h. 
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General Procedures for generation of the thioether linkage in protected SRH target compounds by 
two methods. 
 
Method A: General procedure for SN2 reactions between thiols and mesylate electrophiles, 
preparative scale (0.70 – 1.5 mmol)69 
To an approximately 100 mM solution of thiol in THF at 0 oC was added KHMDS (15% w/w in PhMe, 
2.4 equiv) dropwise by addition funnel over ten min. The reaction mixture was then moved to ambient 
temperature and stirred for 30 min. The reaction mixture was returned to 0 oC, and an approximately 1 M 
solution of mesylate electrophile 20a or 30 (2 equiv) in THF was added in one portion via cannula. The 
reaction mixture was moved to ambient temperature and stirred. After monitoring by TLC (1:3 
EtOAc/hexanes) indicated consumption of the thiol, the reaction mixture was quenched with saturated aq. 
NH4Cl (20 mL) and stirred for 30 min. The reaction was then poured onto dH2O (40 mL) and extracted 
with four portions of CH2Cl2 (75 mL). The combined organic layers were washed with five portions of 
water (75 mL), then 75 mL brine. The organic layer was dried over anhydrous MgSO4, and filtered. 
Concentration via rotary evaporation was facilitated by the addition of ethanol (30 mL). 
 
Method B: General procedure for TEC reactions of vinyl glycine derivative with thiol, (0.15 mmol 
scale) 
Adapted from published procedure.62,64 Vinyl glycine derivative 32 (1 equiv) and thiol 31 (2-3 equiv) 
were dissolved in anhydrous CH2Cl2 (1.0 M thiol) and transferred to a flat-bottomed test tube (10.5 mm 
diameter, 0.7 mm wall thickness) sealed with a rubber septum with an argon balloon. A solution of DPAP 
(15-25 mol% of thiol) in an equal volume of anhydrous CH2Cl2 was added, and the reaction stirred under 
UV radiation at 365 nm. After monitoring by TLC for the disappearance of the limiting reagent, the 
reaction was stopped by solvent removal in vacuo. 
 
 
General procedure for preparation of ribose halides 
Halides 20d, 20e, and 20f were prepared from the mesylate 20a with modifications to literature 
procedures.73,74 In general: To an approximately 100 mM solution of 20a in DMF was added 10 
equivalents of the relevant halide salt in one portion. The reaction was refluxed and monitored to 
completion by TLC (1:1 EtOAc/hexanes). After the reaction mixture cooled to room temperature, it was 
partitioned between diethyl ether (50 mL) and dH2O (25 mL). The organic layer was washed with four 
portions of dH2O (25 mL) and one portion of brine (25 mL).  The organic layer was dried over MgSO4 
and filtered, and the solvent was removed via rotary evaporation. 
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N-tert-butoxycarbonyl-L-homocysteine, tert-butyl ester (7) From General procedure for TCEP-
mediated reductions, isolated as a clear oil from disulfide 34 (0.280 g, 0.961 mmol, 92.9%).  TLC (1:3 
EtOAc/hexanes): Rf 0.53; 1H NMR (500 MHz, CDCl3): δ 5.05 (br d, J = 7.1 Hz, 1H, -NH), 4.31 (m, 1H, 
H-1); 2.58 (m, 2H, H-3), 2.08 (m, 1H, H-2a), 1.90 (m, 1H, H-2b), 1.59 (m, 1H, -SH), 1.47 (s, 9H, H-4 or 
H-5), 1.45 (s, 9H, H-4 or H-5); 13C NMR (125 MHz, CDCl3): δ 171.6, 155.6, 82.4, 80.0, 53.1, 37.8, 28.5, 
28.1, 20.9; IR (ATR): 3351, 2978, 2935, 1698, 1502, 1366 cm-1. NMR spectra are consistent with 
published report.47 
 
 
 
 
 
1-O-methyl-2,3-O-isopropylidene-D-ribofuranoside (17) Prepared from D-ribose according to literature 
procedures.70 D-ribose (6.987 g, 46.54 mmol) was dissolved in a 60 mL solution of 1:1 methanol/acetone.  
Approximately 1 mL of concentrated HCl was added dropwise before reaction was heated to reflux for 90 
min.  The reaction was monitored by TLC (2:1 EtOAc/hexanes) and allowed to cool to room temperature 
upon consumption of starting material.  The reaction mixture was brought to pH 6 with pyridine and 
concentrated by rotary evaporation.  The crude material was partitioned between ethyl acetate (40 mL) 
and dH2O (100 mL).  The aqueous layer was extracted with three portions of ethyl acetate (40 mL), and 
the organic layers were combined and washed with saturated aq. CuSO4 (75 mL), two portions of dH2O 
(75 mL), and brine (75 mL), and dried over MgSO4.  After filtration, the product was concentrated by 
rotary evaporation and isolated as a light yellow oil after short-path distillation (4.299 g, 21.05 mmol, 
45.2%) but crude material (5.738 g, 28.10 mmol, 60.4%) was typically used to prepare sulfonates 20a and 
20b.  TLC (2:1 EtOAc/hexanes): Rf 0.44; 1H NMR (500 MHz, CDCl3): δ 4.97 (s, 1H, H-1), 4.84 (d, J = 
6.0 Hz, 1H, H-2), 4.59 (d, J = 6.0 Hz, 1H, H-3), 4.44 (~t, 1H, H-4), 3.70 (m, 1H, H-5a), 3.62 (m, 1H, H-
5b), 3.44 (s, 3H, -OMe), 3.22 (dd, J = 10.8, J = 2.5 Hz, 1H, -OH), 1.49 (s, 3H, H-6a), 1.32 (s, 3H, H-6b); 
13C NMR (125 MHz, CDCl3): δ 112.2, 110.1, 88.5, 85.9, 81.6, 64.1, 55.6, 26.5, 24.8; IR (NaCl): 3460, 
2989, 2941, 2837, 1456, 1374 cm-1. All analytical data are consistent with published report.97  
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N,N’-Di(tert-butoxycarbonyl)-L,L-homocystine, bis(methyl) ester (18) Work performed by Megan 
Bolitho. Prepared with modification of published procedures.40 Thionyl chloride (10 mL, 137.8 mmol) 
was added dropwise to dry methanol (100 mL, distilled from Mg) over a period of 15 min at 0 oC. The 
reaction mixture was moved to room temperature for 15 min. After returning the reaction mixture to 0 oC, 
L,L-homocystine (3.00 g, 11.2 mmol) was added in one portion. The reaction mixture was allowed to 
warm to room temperature and stirred overnight. The reaction was monitored by TLC (1:1 
MeOH/CH2Cl2) for consumption of starting material, and concentration under reduced pressure yielded a 
thick foamy solid. Deionized water (10 mL) and dioxane (10 mL) were added to the crude material under 
ambient conditions and the mixture stirred until homogeneous. A 1 M aq. solution of Na2CO3 was added 
in 1 mL aliquots at 0 oC until the pH of the reaction increased to pH 9. A solution of di-tert-butyl 
dicarbonate (5.95 g, 27.3 mmol) in dioxane (10 mL) was added dropwise to the reaction mixture over 15 
min, at which time the pH of the reaction mixture had dropped to pH 7.5.  Additional 1 mL aliquots of 1 
M Na2CO3 were added to return the solution to pH 9, and the reaction mixture was allowed to warm to 
room temperature. Monitoring by TLC (1:4 MeOH/CH2Cl2) indicated consumption of starting material 
after stirring overnight. The reaction was extracted with three portions of CH2Cl2 (100 mL). The 
combined organic layers were dried over MgSO4, filtered, and concentrated under reduced pressure to a 
yellow liquid. The crude material was taken up in EtOAc (150 mL), washed with three portions of 
saturated aq. NaHCO3 (75 mL) and brine (75 mL) and dried over MgSO4. After filtration, concentration 
under reduced pressure resulted in a white solid which was recrystallized from EtOAc/hexanes (3.79 g, 
7.63 mmol, 68.1%). The solid powder is stable indefinitely at room temperature. TLC (1:1 
EtOAc/hexanes): Rf 0.44; mp 96-98 oC; 1H NMR (500 MHz, CDCl3): δ 5.12 (br d, J = 5.6 Hz, 2H, -NH), 
4.40 (br s, 2H, H-1), 3.76 (s, 6H, H-5), 2.71 (m, 4H, H-3), 2.24 (m, 2H, H-2a), 1.99 (m, 2H, H-2b), 1.44 (s, 
18H, H-4); 13C NMR (125 MHz, CDCl3): δ 172.8, 155.5, 80.3, 77.4, 52.6, 34.7, 32.7, 28.4; IR (ATR): 
3364, 2984, 1752, 1683, 1516, 1436, 1366 cm-1. Analytical data are largely consistent with published 
reports.98  
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N-tert-butoxycarbonyl-S-(5-deoxy-1-O-methyl-2,3-O-isopropylidene-D-ribofuranos-5-yl)-L-
homocysteine, methyl ester (19a) From General Procedures for generation of the thioether linkage 
in protected SRH target compounds by two methods. Method A: From thiol 22 (0.250 g, 1.003 mmol) 
and mesylate 20a after overnight stir: Silica gel flash column chromatography in 1:3 EtOAc : hexanes 
provided protected SRH derivative 19a as a colorless oil (0.024 g, 0.055 mmol, 5.5%). TLC (1:3 EtOAc : 
hexanes): Rf 0.18; 1H NMR (500 MHz, CDCl3): δ 5.11 (br d, J = 8.9 Hz, 1H, -NH), 4.97 (s, 1H, H-1), 
4.69 (d, J = 6.0 Hz, 1H, H-3), 4.60 (d, J = 6.0 Hz, 1H, H-2), 4.42 (br s, 1H, H-1’), 4.23 (dd, J = 9.5 Hz, J 
= 6.2 Hz, 1H, H-4), 3.75 (s, 3H, H-5’), 3.34 (s, 3H, -OMe), 2.75 (ddd, J = 13.5 Hz, J = 6.2 Hz, J = 2.9 Hz, 
1H, H-5a), 2.59 (m, 3H, H-3’ and H-5b), 2.12 (m, 1H, H-2’a), 1.92 (m, 1H, H-2’b), 1.48 (s, 3H, H-6a), 1.45 
(s, 9H, H-4’), 1.32 (s, 3H, H-6b); 13C NMR APT (125 MHz, CDCl3): δ 112.6, 109.8, 85.9, 85.4, 83.5, 
55.1, 52.9, 52.6, 35.9, 35.8, 33.0, 32.9, 28.5, 28.0, 27.9, 26.6, 25.1; IR (ATR) 3348, 2978, 2935, 1743, 
1713, 1512, 1367 cm-1; Previously reported without analytical data.59 1H NMR peak assignments were 
made after analysis by COSy 1H NMR. 
 
 
 
 
 
N-tert-butoxycarbonyl-S-(5-deoxy-1-O-methyl-2,3-O-isopropylidene-D-ribofuranos-5-yl)-L-
homocysteine, tert-butyl ester (19b) From General Procedures for generation of the thioether 
linkage in protected SRH target compounds by two methods. Method A: Reported values from work 
performed by Megan Bolitho. Using thiol 7 (0.438 g, 1.50 mmol) and mesylate 20a after overnight stir: 
Silica gel flash column chromatography (1:5 EtOAc: hexanes) provided protected SRH derivative 19b as 
a white oil (0.330 g, 0.691 mmol, 46.1%). Using thiol 31 (0.335 g, 1.52 mmol), and mesylate 30 after 2 h 
stir: Silica gel flash column chromatography (1:3 EtOAc/hexanes) afforded a yellow oil (0.411 g, 0.861 
mmol, 56.6%). Method B: Using vinylglycine 32 (0.040 g, 0.155 mmol) and thiol 31 (0.099 g, 0.449 
mmol) with 25 mol% DPAP after irradiation at 365 nm for 1.5 h: Reaction was purified by flash column 
chromatography (1:10 EtOAc : hexanes) to obtain 19b as a viscous, colorless oil (0.069 g, 0.144 mmol, 
93.2%). TLC (1:3 EtOAc: hexanes): Rf 0.39; 1H NMR (500 MHz, CDCl3, δ): 5.09 (br d, 1H, -NH), 4.96 
(s, 1H, H-1), 4.69 (d, J = 5.9 Hz, 1H, H-3), 4.59 (d, J = 5.9 Hz, 1H, H-2), 4.23 (m, 2H, H-1’ and H-4), 
3.33 (s, 3H, -OMe), 2.75 (dd, J = 13.4 Hz, J = 6.2 Hz, 1H, H-5a), 2.58 (m, 3H, H-3’ and H-5b), 2.08 (m, 
1H, H-2’a), 1.87 (m, 1H, H-2’b), 1.46 (s, 12H, H-6a and H-4’ or H-5’), 1.44 (9H, H-4’ or H-5’), 1.31 (s, 
3H, H-6b’); 13C NMR (125 MHz, CDCl3): δ 171.4, 155.5, 112.6, 109.7, 85.9, 85.4, 83.4, 82.4, 80.0, 55.1, 
53.5, 35.8, 28.5, 28.2, 28.1, 27.9, 26.6, 25.2; IR (NaCl): 3362, 2979, 2934, 1716 (br.) 1505, 1368 cm-1; 
ESI-HRMS (m/z): [M+H]+ calcd for C22H39NO8S, 478.2469, found 478.2470. 1H NMR peak assignments 
were made after analysis by COSy 1H NMR. 
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1-O-methyl-2,3-O-isopropylidene-5-O-(methanesulfonyl)-β-D-ribofuranoside (20a) Prepared from 
protected ribose derivative 17 according to modified literature procedures.71 Protected ribose 17 (1.733 g, 
8.487 mmol) was dissolved in CH2Cl2 (250 mL) and cooled to 0 oC. Triethylamine (3.6 mL, 25.8 mmol) 
was added in one portion, and the solution was allowed to stir for 10 min before the dropwise addition of 
methanesulfonyl chloride (1.0 mL, 12.9 mmol).  Monitoring by TLC (1:1 EtOAc/hexanes) indicated full 
conversion of starting material after the reaction had stirred at 0 oC for 35 min.  The reaction mixture was 
poured onto saturated aq. NaHCO3 (100 mL), and the aqueous layer was extracted with three portions of 
CH2Cl2 (50 mL).  Organic fractions were pooled, washed with one portion of brine (100 mL), dried over 
MgSO4, filtered, and the solvent was removed by rotary evaporation to give the crude product as an 
orange solid.  Recrystallization from hot ethanol gave fluffy white crystals (1.868 g, 6.617 mmol, 78%). 
The solid product is stable for ~6 weeks under refrigeration with decomposition evident after several 
months. TLC (1:1 EtOAc/hexanes):  Rf 0.42; mp 78-80 oC, lit.74 78-79 oC; 1H NMR (500 MHz, CDCl3): δ 
4.99 (s, 1H, H-1), 4.70 (d, J = 5.8 Hz, 1H, H-2), 4.61 (d, J = 5.9 Hz, 1H, H-3), 4.41 (~t, 1H, H-4), 4.21 (d, 
J = 7.7 Hz, 2H, H-5), 3.35 (s, 3H, -OMe), 3.07 (s, 3H, -OMs), 1.49 (s, 3H, H-6a), 1.32 (s, 3H, H-6b); 13C 
NMR APT (125 MHz, CDCl3): δ 113.0, 109.8, 85.1, 84.0, 81.5, 68.6, 55.4, 38.0, 26.6, 25.1; IR (ATR): 
3032, 2991, 2944, 2923, 1379, 1349 cm-1. All spectral data are consistent with published reports.99 
 
 
 
 
 
1-O-methyl-2,3-O-isopropylidene-5-O-(p-toluenesulfonyl)-β-D-ribofuranoside (20b) Compound 20b 
was prepared from protected ribose derivative 17 according to modified literature procedures.41 p-
toluenesulfonyl chloride (1.413 g, 7.412 mmol) was added to a stirred solution of the protected ribose 
derivative 17 (0.757 g, 3.707 mmol) in pyridine (8 mL) at 0 oC. The reaction gradually moved to room 
temperature while stirring for 26 h.  Monitoring by TLC (1:1 EtOAc/hexanes) revealed no visible starting 
material remaining, and the pyridine was coevaporated with three portions of toluene (8 mL) by rotary 
evaporation. The crude product was taken up in EtOAc (60 mL), washed with two portions of saturated 
aq. NaHCO3 (25 mL) and one portion of brine (25 mL). The organic layer was dried over MgSO4, 
filtered, and solvent was removed by rotary evaporation. Product 20b was isolated as fibrous white 
crystals after recrystallization from hot ethanol (0.984 g, 2.746 mmol, 74.1%). The solid product is stable 
indefinitely with refrigeration. TLC (1:3 EtOAc/hexanes): Rf 0.28; mp 82-83 oC, lit.88 80-81 oC; 1H NMR 
(500 MHz, CDCl3): δ 7.81 (d, J = 7.9 Hz, 2H, H-7), 7.36 (d, J = 7.9 Hz, 2H, H-8), 4.93 (s, 1H, H-1), 4.60 
(d, J = 5.6 Hz, 1H, H-2), 4.53 (d, J = 5.8 Hz, 1H, H-3), 4.31 (~t, 1H, H-4), 4.02 (m, 2H, H-5), 3.24 (s, 3H, 
-OMe), 2.46 (s, 3H, H-9), 1.45 (s, 3H, H-6a), 1.29 (s, 3H, H-6b); 13C NMR APT (125 MHz, CDCl3): δ 
145.2, 132.9, 130.1, 128.1, 112.9, 109.6, 85.0, 83.7, 81.5, 69.3, 55.2, 26.5, 25.0, 21.8; IR (ATR): 2991, 
2947, 1597, 1385, 1357 cm-1. Analytical data are largely consistent with published reports.88  
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1-O-methyl-2,3-O-isopropylidene-5-O-(trifluoromethanesulfonyl)-β-D-ribofuranoside (20c) Modified 
from published procedure.72 To a solution of pyridine (0.20 mL, 2.48 mmol) and CH2Cl2 (8.0 mL) at -10 
oC was added dropwise trifluoromethanesulfonic anhydride (0.37 mL, 2.20 mmol). A solution of 
protected ribose 17 (0.225g, 1.10 mmol) in anhydrous CH2Cl2 (2.0 mL) was added dropwise and stirred at 
-10 oC. After 1.5 h, monitoring by TLC (1:1 EtOAc/hexanes) indicated consumption of starting material 
17. To the reaction was added cold dH2O (10 mL). The aqueous layer was extracted with three portions of 
CH2Cl2 (10 mL). Organic layers were pooled and washed with dH2O (15 mL) and brine (20 mL), dried 
over MgSO4, filtered, and concentrated in vacuo to a yellow-brown oil as crude product (0.383 g, 1.14 
mmol, quantitative). Product decomposed rapidly overnight under refrigeration. TLC (1:1 
EtOAc/hexanes): Rf 0.68; 1H NMR (500 MHz, CDCl3): δ 5.02 (s, 1H, H-1), 4.68 (d, J = 5.9 Hz, 1H, H-2), 
4.62 (d, J = 5.9 Hz, 1H, H-3), 4.47 (m, 3H, H-4 and H-5), 3.36 (s, 3H, -OMe), 1.49 (s, 3H, H-6a), 1.33 (s, 
3H, H-6b). 1H NMR data are consistent with published reports.72 
 
 
 
 
 
1-O-methyl-2,3-O-isopropylidene-5-chloro-5-deoxy-D-ribofuranoside (20d) From General procedure 
for preparation of ribose halides using LiCl, 90 min. reflux. Product was isolated as a yellow oil after 
silica gel flash column chromatography with 1:3 EtOAc/hexanes (0.514 g, 2.308 mmol, 82.2%). TLC (1:3 
EtOAc/hexanes): Rf 0.63; 1H NMR (500 MHz, CDCl3): δ 4.98 (s, 1H, H-1), 4.74 (d, J = 5.9 Hz, 1H, H-2), 
4.60 (d, J = 6.0 Hz, 1H, H-3), 4.31 (dd, J = 9.7, J = 6.0 Hz, 1H, H-4), 3.55 (m, 1H, H-5a), 3.46 (m, 1H, H-
5b), 3.33 (s, 3H, -OMe), 1.48 (s, 3H, H-6a), 1.32 (s, 3H, H-6b); 13C NMR APT (125 MHz, CDCl3): δ 
112.8, 109.6, 86.8, 85.2, 82.3, 55.2, 44.3, 26.5, 25.1; IR (NaCl): 2990, 2939, 2836, 1728, 1450, 1382, 
1375 cm-1. ESI-HRMS (m/z): [M+H]+ calcd for C9H15ClO4, 223.0732, found 223.0734.  
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1-O-methyl-2,3-O-isopropylidene-5-bromo-5-deoxy-D-ribofuranoside (20e) From General procedure 
for preparation of ribose halides using LiBr, 30 min. reflux.73 Product was isolated as a yellow oil after 
silica gel flash column chromatography with 1:1 EtOAc/hexanes (0.172 g, 0.644 mmol, 64.7%). TLC (1:1 
EtOAc/hexanes): Rf 0.63; 1H NMR (500 MHz, CDCl3): δ 5.01 (s, 1H, H-1), 4.77 (d, J = 5.8 Hz, 1H, H-2), 
4.62 (d, J = 5.9 Hz, 1H, H-3), 4.39 (dd, J = 10.0, J = 5.9 Hz, 1H, H-4), 3.43 (m, 1H, H-5a), 3.35 (s, 3H, -
OMe), 3.32 (m, 1H, H-5b), 1.49 (s, 3H, H-6a), 1.33 (s, 3H, H-6b); 13C NMR APT (125 MHz, CDCl3): δ 
112.8, 109.7, 86.8, 85.3, 82.7, 55.2, 32.6, 26.5, 25.1; IR (NaCl): 2990, 2938, 2835, 1731, 1382, 1374 cm-
1. NMR data are largely consistent with published reports.88  
 
 
 
 
 
1-O-methyl-2,3-O-isopropylidene-5-iodo-5-deoxy-D-ribofuranoside (20f) From General procedure 
for preparation of ribose halides using NaI (dried), 45 min. reflux.74 Product isolated as a yellow oil 
after silica gel flash column chromatography with 1:1 EtOAc/hexanes (0.460 g, 1.465 mmol, 79.1%). 
TLC (1:1 EtOAc/hexanes): Rf 0.64; 1H NMR (500 MHz, CDCl3): δ 5.05 (s, 1H, H-1), 4.77 (d, J = 5.9 Hz, 
1H, H-2), 4.63 (d, J = 5.9 Hz, 1H, H-3), 4.44 (dd, J = 10.0, J = 6.1 Hz, 1H, H-4), 3.37 (s, 3H, -OMe), 3.29 
(m, 1H, H-5a), 3.16 (m, 1H, H-5b), 1.48 (s, 3H, H-6a), 1.33 (s, 3H, H-6b); 13C NMR APT (125 MHz, 
CDCl3): δ 112.8, 109.8, 87.6, 85.5, 83.2, 55.4, 26.6, 25.1, 6.8; IR (NaCl): 2989, 2937, 2833, 1382, 1374 
cm-1. All analytical data are consistent with published report.100  
 
 
 
 
 
N-tert-butoxycarbonyl-L-homocysteine, methyl ester (22) From General procedure for TCEP-
mediated reductions, isolated as a clear yellow oil from disulfide 18 (0.495 g, 1.985 mmol, 96.7%). TLC 
(1:2 EtOAc/hexanes): Rf 0.29; 1H NMR (500 MHz, CDCl3): δ 5.06 (br d, J = 7.1 Hz, 1H, -NH), 4.47 (m, 
1H, H-1), 3.76 (s, 3H, H-5), 2.59 (m, 2H, H-3), 2.11 (m, 1H, H-2a), 1.93 (m, 1H, H-2b), 1.57 (m, 1H, -
SH), 1.45 (s, 9H, H-4); 13C NMR APT (125 MHz, CDCl3): δ 173.0, 155.5, 80.3, 52.6, 52.4, 37.4, 28.5, 
20.9; IR (ATR): 3357, 2977, 2571, 1740, 1698, 1513, 1165 cm-1. All analytical data are consistent with 
published reports.98 
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1-O-methyl-2,3-O-isopropylidene-4-methylene-β-D-erythrofuranoside (26) Independently synthesized 
with modifications to published procedures.88 Mesylated ribose derivative 20a (0.342 g, 1.21 mmol) was 
dissolved in THF (12 mL) and cooled to 0 oC. A solution of potassium tert-butoxide (2.0 mL, 1 M in 
THF, 2.0 mmol) was added in one portion. The reaction stirred at room temperature for 1.5 h before 
vacuum filtration. After the filtrate was evaporated under reduced pressure, the crude product remained a 
colorless oil. Product 26 was purified to afford a colorless oil after silica gel flash column 
chromatography in 1:9 EtOAc/hexanes (0.159 g, 0.854 mmol, 70.6%) TLC (1:9 EtOAc/hexanes): Rf 0.38; 
1H NMR (500 MHz, CDCl3): δ 5.11 (s, 1H, H-1), 5.02 (d, J = 5.9 Hz, 1H, H-2), 4.60 (s, 1H, H-5a), 4.50 
(d, J = 5.9 Hz, 1H, H-3), 4.39 (s, 1H, H-5b), 3.41 (s, 3H, -OMe), 1.47 (s, 3H, H-6a), 1.35 (s, 3H, H-6b); 13C 
NMR APT (125 MHz, CDCl3): δ 161.3, 113.3, 108.4, 88.8, 82.8, 78.8, 55.8, 26.8, 25.8; IR (NaCl): 2990, 
2939, 2840, 1672, 1457, 1383, 1374 cm-1. NMR data are largely consistent with published report.88 
 
 
 
 
 
N-(tert-butoxycarbonyl)-O-(methanesulfonyl)-L-homoserine, 1-tert-butyl ester (30) Work performed 
by Diana Cudia. Modified from published procedure.81 Homoserine derivative 39 (1.351 g, 4.91 mmol) 
was dissolved in dry CH2Cl2 (45 mL) and cooled to 0 oC. TEA (1.4 mL, 10.04 mmol) and mesyl chloride 
(0.8 mL, 10.34 mmol) were added successively to the cooled solution. The reaction was warmed to room 
temperature and stirred overnight (21 h). After monitoring by TLC (1:1 EtOAc/hexanes) indicated 
completion of the reaction, the solution was concentrated in vacuo and the resulting yellow oil was 
dissolved in CH2Cl2 (30 mL). The solution was washed with three portions of dH2O (40 mL) and the 
combined aqueous layers were extracted with three portions of CH2Cl2 (40 mL). The organic layers were 
pooled and dried over anhydrous MgSO4 and filtered. Crude product 30 was isolated after rotary 
evaporation as a yellow solid. After recrystallization from hexanes/CH2Cl2 (160 mL/25 mL), the product 
was isolated as white needle-like crystals (1.327 g, 3.75 mmol, 76.5%).  TLC (1:1 EtOAc/hexanes): Rf 
0.50; mp 91-93 oC, lit.101 85-87 oC; 1H NMR (500 MHz, CDCl3): δ 5.16 (br d, J = 6.7 Hz, 1H, -NH), 4.30 
(m, 3H, H-1 and H-3), 3.03 (s, 3H, -OMs), 2.31 (m, 1H, H-2a), 2.06 (m, 1H, H-2b), 1.48 (s, 9H, H-4 or H-
5), 1.45 (s, 9H, H-4 or H-5); 13C NMR (125 MHz, CDCl3): δ 110.2, 83.0, 66.3, 51.1, 37.5, 32.4, 28.5, 
28.1; IR (ATR): 3384, 3008, 2992, 2977, 2944, 1736, 1715, 1515, 1342 cm-1. NMR spectra are consistent 
with published reports.101 
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1-O-methyl-2,3-O-isopropylidene-5-thio-β-D-ribofuranoside (31) Thioacetate 40 was deprotected into 
thiol 31 with modifications to a published procedure.84 Thioacetate 40 (0.260 g, 0.991 mmol) was 
dissolved in MeOH (10 mL) and cooled to -15 °C. A commercial solution of 5.4 M sodium methoxide in 
methanol (0.51 mL, 2.754 mmol) was added dropwise to the solution. The reaction was allowed to stir for 
15 minutes and monitored by TLC (1:3 EtOAc/hexanes) to indicate consumption of starting material. 
Reaction was moved to room temperature and Amberlite resin IR-120 was quickly added until pH was 
neutral by pH paper. The resin was filtered off by vacuum filtration, and the solvent was removed under 
reduced pressure. The resulting crude product was a mixture of thiol 31 and the corresponding oxidized 
product 43. Purification by silica gel flash column chromatography (1:10 " 1:5  EtOAc/hexanes) 
afforded thiol 31 as a clear oil (0.112 g, 0.508 mmol). The recovered disulfide product 43 (0.090 g, 0.205 
mmol, see below) was subjected to TCEP-mediated reduction: To a ~68 mM solution of 43 in DMF (3 
mL) was added a solution of TCEP.HCl in ddH2O (1 mL). The reaction stirred overnight, and was 
monitored by TLC (1:3 EtOAc/hexanes) after 19 h to indicate full conversion of the disulfide. The 
solution was poured onto brine (10 mL) and the aqueous solution was extracted with diethyl ether in 
series (20 mL, then 3 x 10 mL). Each individual ether layer was washed with four portions of dH2O (10 
mL). The combined washed organic fractions were pooled, washed with brine (25 mL), dried over 
MgSO4, filtered, and concentrated by rotary evaporation. The resulting product matched the thiol 31 by 
1H NMR and required no further purification. It was pooled with the thiol isolated after the column to 
afford 31 with an overall yield of 0.199 g (0.903 mmol, 91.2%). TLC (1:3 EtOAc/hexanes): Rf 0.49; 1H 
NMR (500 MHz, CDCl3): δ 4.97 (s, 1H, H-1), 4.70 (d, J = 5.9 Hz, 1H, H-3), 4.60 (d, J = 5.9, 1H, H-2), 
4.18 (t, J = 7.7 Hz, 1H, H-4), 3.36 (s, 3H, -OMe), 2.79 (m, 1H, H-5a), 2.56 (m, 1H, H-5b), 1.49 (s, 3H, H-
6a), 1.33 (s, 3H, H-6b); 13C NMR APT (125 MHz, CDCl3): δ 112.7, 109.7, 89.0, 85.4, 83.1, 55.3, 28.4, 
26.6, 25.2; IR (ATR): 2989, 2937, 2834, 2565, 1442, 1373 cm-1. 1H NMR data are consistent with 
published report.102 
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N-(tert-butoxycarbonyl)-L-vinylglycine, tert-butyl ester (32) Modified from published procedures.93 
Selenide 42 (0.526 g, 1.15 mmol) was dissolved in THF (38 mL) and cooled to -5 oC on a NH4Cl ice bath 
for 10 min. A solution of 30% H2O2 (11.6 mL) was added dropwise to the solution and allowed to stir at   
-5 oC. When TLC monitoring (1:3 EtOAc/hexanes) indicated incomplete consumption of starting material 
after 1 h at -5 oC, the reaction was moved to room temperature and stirred for 2.5 h. Again, the reaction 
was cooled to, and an additional portion of 30% H2O2 (10.0 mL) was added dropwise. After 30 min, TLC 
indicated consumption of starting material. The reaction was extracted with three portions of ether (50 
mL). Organic layers were pooled and washed with one portion each of dH2O (50 mL) and brine (50 mL), 
dried over MgSO4, filtered and concentrated in vacuo to a yellow solid coexisting with a clear oil. 
Residue was purified by flash column chromatography (93:7 hexanes/ether) to isolate the product 32 as a 
clear oil (0.211 g, 0.82 mmol, 71.6%). TLC (1:3 EtOAc/hexanes): Rf 0.47; 1H NMR (500 MHz, CDCl3): 
δ 5.89 (m, 1H, H-2), 5.33 (d, J = 17.0 Hz, 1H, H-3cis), 5.22 (d, J = 10.4 Hz, 1H, H-3trans), 5.18 (br s, 1H,    
-NH), 4.73 (br s, 1H, H-1), 1.47 (s, 9H, H-4 or H-5), 1.45 (s, 9H, H-4 or H-5); 13C NMR (125 MHz, 
CDCl3): δ 169.9, 155.2, 133.5, 116.8, 82.5, 80.0, 56.4, 28.5, 28.1; IR (ATR): 3368, 2979, 2934, 1712, 
1494, 1367 cm-1. 1H NMR data are consistent with published report.93 
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N,N’-Di(tert-butoxycarbonyl)-L,L-homocystine, bis(tert-butyl) ester (34) Work performed by Emily 
Showell-Rouse with modification of published procedure.47,68 To a solution of L,L-homocystine (1.00 g, 
3.73 mmol) in 1 M aqueous sodium carbonate (33.5 mL) was added dioxane (30 mL) under ambient 
conditions. Di-tert-butyl dicarbonate (1.72 g, 7.88 mmol) was added in one portion.  The cloudy reaction 
mixture was stirred overnight at room temperature. A 10% w/v solution of aqueous citric acid was added 
to the milky reaction mixture dropwise at 0 oC. During acidification, the reaction mixture first clarifies 
while visibly evolving gas (to pH ~ 5.5) and then becomes gelatinous (at pH ~ 4.5). The gelled product 
was extracted with four portions of EtOAc (40 mL). The organic layers were combined and washed with 
five portions of dH2O and one portion of brine (40 mL) and dried over MgSO4. After filtration, solvent 
was removed via rotary evaporation to afford a dry, crusty white solid as the intermediate N,N’-di(tert-
butoxycarbonyl)-L,L-homocystine) in good yield (1.52 g, 3.24 mmol, 86.9%). The crude intermediate 
(1.43 g, 3.05 mmol) was then suspended in 35 mL CH2Cl2 and placed at 0 oC. Reagent tert-butyl-2,2,2-
trichloroacetimidate (2.8 mL, 15.6 mmol) was added in one portion and the reaction allowed to warm to 
room temperature. After stirring overnight, the reaction mixture was cooled to low temperature (i.e. -80 
oC), and the bulk of byproduct 2,2,2-tert-butyltrichloroacetimide was removed by filtration. The crude 
material was concentrated to a thick yellow oil by rotary evaporation. Residual byproduct was removed 
by filtration from warm hexanes (40 – 50 oC); the product 34 was then isolated after trituration from cold 
hexanes (1.51 g, 2.60 mmol, 70% over two steps) as a white powder. The solid powder is stable 
indefinitely at room temperature. TLC (2:1 EtOAc/hexanes): Rf 0.76; mp 65 – 68 oC, lit.68 66-68 oC; 1H 
NMR (500 MHz, CDCl3): δ 5.10 (br d, J = 5.4 Hz, 2H, -NH), 4.26 (m, 2H, H-1), 2.69 (m, 4H, H-3), 2.20 
(m, 2H, H-2a), 1.98 (m, 2H, H-2b), 1.48 (s, 18H, H-4 or H-5), 1.45 (s, 18H, H-4 or H-5); 13C NMR (125 
MHz, CDCl3): δ 171.4, 155.5, 82.4, 80.0, 53.4, 34.7, 33.1, 28.5, 28.2; IR (ATR): 3389, 2981, 2937, 1742, 
1690, 1506, 1366 cm-1. NMR data are consistent with published reports.47 
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N-(tert-butoxycarbonyl)-L-aspartic acid, 4-methyl ester, 1-tert-butyl ester (37) Work performed in 
collaboration with Diana Cudia and Emily Murzinski from modified literature procedures.40,79,80 Thionyl 
chloride (0.33 mL, 4.52 mmol) was added dropwise to anhydrous MeOH (33 mL) over 10 min at 0 oC.  L-
aspartic acid (0.550 g, 4.132 mmol) was added, and the reaction was warmed to room temperature. The 
reaction stirred for 3.5 h and was monitored by TLC (MeOH). The crude material was concentrated in 
vacuo to afford initial intermediate product 35 (L-aspartic acid, 4-methyl ester) in quantitative yield 
(0.855 g, 5.81 mmol) as a white solid. Intermediate 35 was then added to a solution of Na2CO3 (0.629 g, 
5.94 mmol) in dioxane (12 mL) and H2O (6 mL) at 0 oC. An additional portion of Na2CO3 (0.628 g, 5.93 
mmol) and (Boc)2O (1.802 g, 8.26 mmol) were added once CO2 evolution ceased. The reaction was 
stirred at 0 oC for 1 h before being warmed to room temperature and continued to stir overnight (16 h). 
Residual dioxane was removed via rotary evaporation, and the residue was poured onto ice-water (100 
mL) and extracted with ether (3 x 50 mL). Saturated aq. NaHSO4 was added to the water layer dropwise 
to acidify to pH ~ 2.5. The aqueous layer was extracted with three portions of ether (50 mL) and organic 
layers were pooled and washed with dH2O (100 mL). The second intermediate 36 (N-(tert-
butoxycarbonyl)-L-aspartic acid, 4-methyl ester) was recovered as a yellow oil after rotary evaporation 
(0.711 g, 2.88 mmol, 69.7% (crude) over 2 steps). Lastly, to a solution of crude 36 (0.200 g, 0.809 mmol) 
in CH2Cl2 (1.7 mL) was added tert-butyl-2,2,2-trichloroacetimidate (0.589 g, 2.696 mmol) at room 
temperature. The reaction was stirred overnight (18.5 h) and monitored to completion by TLC (1:1 
EtOAc/hexanes). The reaction mixture was cooled to 0 oC. The solid white byproduct was removed by 
vacuum filtration and the fully-protected aspartic acid derivative 37 was isolated as yellow crystals after 
filtration from hot hexanes (0.232 g, 0.765 mmol, 65.9% (from crude) over three steps. TLC (1:1 
EtOAc/hexanes; ninhydrin stain): Rf 0.57; mp 49-51 oC, lit.80 52-54 oC; 1H NMR (500 MHz, CDCl3): δ 
5.43 (br d, J = 7.1 Hz, 1H, -NH), 4.44 (m, 1H, H-1), 3.68 (s, 3H, -OMe), 2.94 (dd, J = 16.6, 3.6 Hz, 1H, 
H-2a), 2.76 (dd, J = 16.6, 4.9 Hz, 1H, H-2b), 1.44 (~d, 18H, H-4 and H-5); 13C NMR APT (125 MHz, 
CDCl3): δ 171.5, 170.1, 155.5, 82.5, 80.0, 52.0, 50.7, 37.1, 28.5, 28.0; IR (ATR): 3409, 2983, 2932, 1736, 
1702, 1502 cm-1. NMR spectra are consistent with published reports.80 
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N-(tert-butoxycarbonyl)-L-aspartic acid, 1-tert-butyl ester (38) Modified from published procedure.79 
The fully protected aspartate derivative 37 (0.700 g, 2.308 mmol) was dissolved in a solution of 6:1 
acetone/dH2O (12.25 mL) at 0 oC. A 1 M aq. solution of NaOH (0.960 mL) was added in 10 µL aliquots 
to maintain a pH ~8.5 – 9. The reaction mixture then stirred at room temperature overnight. The reaction 
was returned to 0 oC, and additional aliquots of 1 M NaOH (0.620 mL) were added before again stirring 
overnight at room temperature. The reaction was returned to 0 oC and a final 0.070 mL 1 M NaOH was 
added in 10 µL aliquots to the solution. The reaction was concentrated by rotary evaporation to ~ 2 mL, 
and the residue was taken up in 4 mL of dH2O and washed with one portion of diethyl ether (10 mL). The 
aqueous layer was brought to 0 oC and acidified to pH 4.5 with dropwise addition of 0.5 M HCl (3.530 
mL).  The white precipitate that formed was extracted with four portions of diethyl ether (10 mL) and the 
combined organic layers were washed with dH2O (10 mL) and brine (10 mL).  The organic layer was 
dried over MgSO4, filtered, and the solvent was removed by rotary evaporation. Product 38 was isolated 
as a white solid after recrystallization from hexanes/ether (15 mL/2 mL), (0.319 g, 1.103 mmol, 47.8%). 
TLC (1:1 EtOAc/hexanes; ninhydrin stain): Rf 0.45; mp 104-105 oC, lit.79 105-106 oC; 1H NMR (500 
MHz, CDCl3): δ 5.45 (br d, J = 7.6 Hz, 1H, -NH), 4.46 (m, 1H, H-1), 3.00 (dd, J = 16.9, 3.2 Hz, 1H, H-
2a), 2.83 (dd, J = 17.1, 3.9 Hz, 1H, H-2b), 1.45 (s, 18H, H-4 and H-5); 13C NMR (125 MHz, CDCl3): δ 
176.1, 169.9, 155.6, 82.7, 80.3, 50.5, 37.0, 28.5, 28.0; IR (ATR): 3423, 2982, 2934, 2702, 2644, 2568, 
1746, 1738, 1694, 1501 cm-1. NMR spectra are consistent with published reports;82 all spectra match 
those of commercial sample. 
 
 
 
 
N-(tert-butoxycarbonyl)-L-homoserine, 1-tert-butyl ester (39) Work performed in collaboration with 
Diana Cudia and Emily Murzinski. Modified from published procedures.81,82  To a stirring solution of N-
(tert-butoxycarbonyl)-L-aspartic acid, 1-tert-butyl ester 38 (0.306 g, 1.11 mmol) in dry THF (3.25 mL) at 
-5 oC was added triethylamine (0.15 mL, 1.08 mmol). Ethyl chloroformate (0.10 mL, 1.05 mmol) was 
added dropwise, and the reaction was allowed to stir at -5 oC. After 45 min, a precipitate had formed and 
was removed via vacuum filtration and washed with 5 mL of anhydrous THF. The resulting filtrate was 
added dropwise over ~20 min to a stirred solution of sodium borohydride (0.096 g, 2.56 mmol) in 0.80 
mL of dH2O at 10-12 ºC. The reaction was allowed to warm to room temperature and stirred for an 
additional 4 h. The solution was brought to 0 oC and acidified to pH 2 with 1 M HCl. The solution was 
extracted with diethyl ether (3 x 10 mL). The combined organic layers were dried with anhydrous MgSO4 
and filtered before concentration by rotary evaporation to give a colorless oil. After purification by silica 
gel flash column chromatography (1:4 EtOAc/hexanes), the protected-homoserine product 39 was 
isolated as a colorless oil (0.218 g, 0.792 mmol, 71.4%) TLC (1:1 EtOAc/hexanes; ninhydrin stain): Rf 
0.65; 1H NMR (500 MHz, CDCl3): δ 5.33 (br d, J = 7.4 Hz, 1H, -NH), 4.36 (m, 1H, H-1), 3.71-3.60 (m, 
2H, H-3), 3.40 (br d, J = 3.9 Hz, 1H, -OH), 2.14 (m, 2H, H-2), 1.47 (s, 9H, H-4 or H-5), 1.45 (s, 9H, H-4 
or H-5); 13C NMR (125 MHz, CDCl3): δ 172.2, 156.8, 82.5, 80.5, 58.4, 51.0, 36.8, 28.4, 28.1; IR (ATR): 
3378, 2978, 2934, 1692, 1501, 1366 cm-1. NMR data are consistent with published report.82   
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S-acetyl-1-O-methyl-2,3-O-isopropylidene-5-thio-β-D-ribofuranoside (40) Adapted with modifications 
to published procedure.83 A mixture of mesylate 20a (0.398 g, 1.41 mmol) and potassium thioacetate 
(0.318 g, 2.78 mmol) in absolute ethanol (14 mL) was heated to reflux for 2.5 days. The reaction refluxed 
for 6 hours per day with 0.5 equivalent of potassium thioacetate added at three hour intervals during the 
reflux period (reaction stirred at room temperature overnight). After consumption of the starting material 
was determined by TLC (1:3 EtOAc/hexanes), heat was removed and the mixture was brought to room 
temperature. The reaction mixture was poured onto CH2Cl2 (20 mL) and washed with dH2O (20 mL). The 
aqueous layer was extracted with three portions of CH2Cl2 (15 mL). The organic layers were pooled, 
washed with 20 mL portions each of dH2O and brine, dried over MgSO4 and filtered. After concentration 
by rotary evaporation, product was recovered as a yellow-white oily solid. Purification by silica gel flash 
column chromatography (1:9 " 1:4 EtOAc/hexanes) afforded thioacetate 40 as a yellow oil (0.267 g, 
1.02 mmol, 72.3%). TLC (1:3 EtOAc : hexanes): Rf 0.43; 1H NMR (500 MHz, CDCl3): δ 4.96 (s, 1H, H-
1), 4.62 (d, J = 5.9 Hz, 1H, H-3), 4.58 (d, J = 5.9, 1H, H-2), 4.19 (t, J = 7.8 Hz, 1H, H-4), 3.35 (s, 3H, -
OMe), 3.02-3.12 (m, 2H, H-5), 2.35 (s, 3H, H-7), 1.45 (s, 3H, H-6a), 1.30 (s, 3H, H-6b); 13C NMR APT 
(125 MHz, CDCl3): δ 194.8, 112.7, 109.9, 85.9, 85.5, 83.4, 55.1, 32.8, 30.7, 26.6, 25.2; IR (ATR): 2989, 
2937, 2834, 1693, 1373 cm-1. 
 
 
 
 
 
N-tert-butoxycarbonyl-S-(5-deoxy-1-O-methyl-2,3-O-isopropylidene-L-lyxofuranos-5-yl)-L-
homocysteine, methyl ester (41) Adapted with modifications to published procedure.63 In a flat-bottom 
test tube (10.5 mm diameter, 0.7 mm wall thickness) with rubber septum, the alkene 26 (0.037 g, 0.199 
mmol) was dissolved in a solution of thiol 22 (0.5 mL, 0.050 g/mL, 0.100 mmol) in anhydrous CH2Cl2 
under an atmosphere of argon. A solution of DPAP (0.5 mL, 0.003 g/mL, 0.012 mmol) in anhydrous 
CH2Cl2 was then added to the reaction. The reaction was again placed under an argon atmosphere, sealed 
with the rubber septum and set to rotate in a carousel irradiated under UV at 365 nm. The tube was 
manually shaken every 5 min for first half hour to ensure adequate mixing. After 2 h, TLC (1:3 
EtOAc/hexanes) indicated apparent consumption of the thiol. The reaction was stopped by solvent 
removal in vacuo. After purification by silica gel flash column chromatography (1:4 EtOAc/hexanes) the 
product 41 was isolated as a colorless oil (0.030 g, 0.069 mmol, 68.9%). TLC (1:3 EtOAc/hexanes): Rf 
0.31; 1H NMR (500 MHz, CDCl3): δ 5.14 (br d, J = 8.1 Hz, 1H, -NH), 4.88 (s, 1H, H-1), 4.71 (dd, J = 
5.9, J = 3.6 Hz, 1H, H-3), 4.56 (d, J = 5.9 Hz, 1H, H-2), 4.40 (m, 1H, H-1’), 4.05 (m, 1H, H-4), 3.75 (s, 
3H, H-5’), 3.33 (s, 3H, -OMe), 2.78-2.87 (m, 2H, H-5), 2.65 (t, J = 7.8 Hz, 2H, H-3’), 2.14 (m, 1H, H-
2’a), 1.96 (m, 1H, H-2’b), 1.46 (s, 3H, H-6a), 1.44 (s, 9H, H-4’), 1.33 (s, 3H, H-6b); 13C NMR APT (125 
MHz, CDCl3): δ 112.8, 107.2, 85.2, 80.2, 80.1, 54.8, 53.0, 52.5, 32.8, 30.0, 28.7, 28.5, 26.3, 25.2; IR 
(ATR): 3359, 2979, 2935, 1744, 1716, 1512, 1367 cm-1.   
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tert-butyl, 2-tert-butoxycarbonylamino-4-(2-nitrophenylselenyl)butanoate (42) Modified from 
published procedure.93 To 2-nitrophenyl selenocyanate (0.796 g, 3.51 mmol) was added a solution of 
protected homoserine intermediate 39 (0.438 g, 1.59 mmol) in dry THF (20 mL). To this mixture was 
added dropwise a solution of tri-n-butyl phosphine (0.54 mL, 2.19 mmol) in dry THF (5 mL) over a 
period of ~5 min. The reaction stirred at room temperature for 105 minutes before monitoring by TLC 
(1:3 EtOAc/hexanes) indicated consumption of starting material 39. The reaction was concentrated by 
rotary evaporation and the remaining residue was purified by silica gel flash column chromatography (9:1     
3:1 hexanes/ether) after which product was recovered as a yellow solid (0.528g, 1.15 mmol, 72.2%). TLC 
(1:3 EtOAc/hexanes; ninhydrin stain): Rf 0.29; 1H NMR (500 MHz, CDCl3): δ 8.30 (d, J = 8.2 Hz, 1H, H-
9), 7.52 (m, 2H, H-6 and H-7), 7.33 (m, 1H, H-8), 5.20 (br d, J = 7.6 Hz, 1H, -NH), 4.32 (m, 1H, H-1), 
2.97 (m, 1H, H-3a), 2.88 (m, 1H, H-3b), 2.29 (m, 1H, H-2a), 2.06 (m, 1H, H-2b), 1.48 (s, 9H, H-4 or H-5), 
1.46 (s, 9H, H-4 or H-5); 13C NMR APT (125 MHz, CDCl3): δ 133.8, 128.9, 126.7, 125.7, 110.2, 82.8, 
54.6, 32.5, 28.5, 28.2, 21.5; IR (ATR): 3390, 2981, 2933, 1718, 1690, 1505 cm-1. 1H NMR data are 
consistent with published report.93  
 
 
 
 
 
Bis(1-O-methyl-5-deoxy-2,3-O-isopropylidene-β-D-ribofuranos-5-yl)-5,5’-disulfide (43) Formed as 
byproduct in synthesis of 31 (see procedure 31 above). TLC (1:3 EtOAc/hexanes): Rf 0.38; 1H NMR (500 
MHz, CDCl3): δ 4.97 (s, 2H, H-1), 4.73 (d, J = 5.9 Hz, 2H, H-3), 4.61 (d, J = 6.0, 2H, H-2), 4.45 (t, J = 
7.6 Hz, 2H, H-4), 3.35 (s, 6H, -OMe), 2.96 (m, 2H, H-5a), 2.78 (m, 2H, H-5b), 1.49 (s, 6H, H-6a), 1.33 (s, 
6H, H-6b); 13C NMR (125 MHz, CDCl3): δ 112.7, 109.8, 85.5, 85.4, 83.3, 55.2, 42.0, 26.6, 25.1; IR 
(ATR): 2992, 2921, 2850, 1736, 1450, 1379 cm-1. 1H NMR data are consistent with published report.102  
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Compound (41) 
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4BJC-1-28_322d 
Sample Name BJC-1-28_322d Pulse sequence gCOSY Temperature 25 Study owner Bolitho 
Date collected 2013-06-28 Solvent cdcl3 Spectrometer Varian-NMR-vnmrs500 Operator Bolitho 
Data file /home/chemusf/vnmrsys/data/Bolitho/BJC/diastereomergCOSY_01.fid Plot date 2015-08-26
F2 (ppm)
1234567
F 1
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